var title_f16_45_17104="CW Doppler from LA in MR";
var content_f16_45_17104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuous wave Doppler in mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The continuous wave Doppler of mitral regurgitation, recorded from the left atrium, shows a jet with a symmetrical shape, suggesting that a significant v-wave in the left atrium is unlikely; however, the jet is dense with a well defined envelope and the early onset of regurgitant flow (arrow), suggesting a moderate degree of regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17104=[""].join("\n");
var outline_f16_45_17104=null;
var title_f16_45_17105="Pancreatic decortication AGA";
var content_f16_45_17105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic decortication AGA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &copy; 2003 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17105=[""].join("\n");
var outline_f16_45_17105=null;
var title_f16_45_17106="Patient information: Whiplash (The Basics)";
var content_f16_45_17106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16964\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/46/15074\">",
"         Anatomy of the neck",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/0/15363\">",
"         Patient information: Neck fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/31/23026\">",
"         Patient information: Neck pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/35/27188\">",
"         Patient information: Neck pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Whiplash (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/whiplash-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11943796\">",
"      <span class=\"h1\">",
"       What is whiplash?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Whiplash is a neck injury that happens when the head suddenly gets jerked forward and then backward. This injury usually happens from car accidents or sports injuries, or when a baby is shaken too hard.",
"     </p>",
"     <p>",
"      A whiplash injury can damage different parts of the neck (",
"      <a class=\"graphic graphic_figure graphicRef72120 \" href=\"UTD.htm?14/46/15074\">",
"       figure 1",
"      </a>",
"      ), such as the:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Ligaments &ndash; Ligaments are tough bands of tissue that connect bones to other bones.",
"       </li>",
"       <li>",
"        Bones &ndash; The neck has 7 bones (called &ldquo;vertebrae&rdquo;) that are stacked on top of each other.",
"       </li>",
"       <li>",
"        Discs &ndash; Discs are cushions that sit between the bones.",
"       </li>",
"       <li>",
"        Nerves &ndash; A bundle of nerves (called the spinal cord) travels down the middle of the spine. Nerves branch off from the spinal cord to all parts of the body.",
"       </li>",
"       <li>",
"        Muscles &ndash; Muscles hold the head up and make the neck move.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11943811\">",
"      <span class=\"h1\">",
"       What are the symptoms of whiplash?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Neck pain",
"       </li>",
"       <li>",
"        Muscle tightness or spasm",
"       </li>",
"       <li>",
"        Being unable to move your neck or turn your head",
"       </li>",
"       <li>",
"        A headache, especially in the back of the head",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11943826\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should see a doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Your symptoms are bothersome or get worse.",
"       </li>",
"       <li>",
"        Your symptoms don&rsquo;t improve after you treat them at home for a few weeks.",
"       </li>",
"       <li>",
"        You have numbness or weakness in your arms or legs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11943841\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor or nurse should be able to tell if you have whiplash by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      Some people with whiplash will need tests. Depending on your symptoms and how long they have lasted, your doctor might do an X-ray, MRI scan, or CT scan. These are imaging tests that can create pictures of the inside of your body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11943856\">",
"      <span class=\"h1\">",
"       How is whiplash treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Whiplash usually gets better on its own within 2 to 3 weeks. But some people have symptoms for longer.",
"     </p>",
"     <p>",
"      To help with your pain and symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take a pain-relieving medicine &ndash; You can use",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;) or a &ldquo;nonsteroidal anti-inflammatory drug&rdquo; (NSAID). NSAIDs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"       <li>",
"        Practice good posture &ndash; Don&rsquo;t carry bags by wearing their shoulder straps on your shoulder. Also, avoid sitting for too many hours at a time. When you do sit, sit up straight and keep your shoulders back. When you sleep, keep your head and neck in line with your body. You might have less pain if you sleep on your back with pillows under your thighs.",
"       </li>",
"       <li>",
"        Do neck stretches and exercises &ndash; Your doctor will show you which stretches and exercises to do, and tell you how often to do them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11943871\">",
"      <span class=\"h1\">",
"       What if my symptoms are severe or don&rsquo;t get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms are severe or don&rsquo;t get better, your doctor might recommend:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &ndash; Your doctor can prescribe strong pain medicines. He or she can also prescribe medicines to relax your muscles (called &ldquo;muscle relaxants&rdquo;) for when you sleep.",
"       </li>",
"       <li>",
"        Physical therapy (working with an exercise expert)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these treatments don&rsquo;t help, your doctor will talk with you about other possible treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11943886\">",
"      <span class=\"h1\">",
"       What treatments are NOT helpful?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most doctors do not recommend that people wear soft neck collars, especially for long periods of time. If a neck collar eases your pain, wear it for less than 3 hours at a time. Wearing a neck collar for too long can make your neck muscles get too weak.",
"     </p>",
"     <p>",
"      Other treatments that are NOT helpful include surgery or a treatment that pulls on the head to lengthen the neck (called &ldquo;cervical traction&rdquo;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11943901\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=see_link\">",
"       Patient information: Neck pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=see_link\">",
"       Patient information: Neck fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=see_link\">",
"       Patient information: Neck pain (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/45/17106?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16964 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17106=[""].join("\n");
var outline_f16_45_17106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11943796\">",
"      What is whiplash?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11943811\">",
"      What are the symptoms of whiplash?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11943826\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11943841\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11943856\">",
"      How is whiplash treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11943871\">",
"      What if my symptoms are severe or don&rsquo;t get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11943886\">",
"      What treatments are NOT helpful?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11943901\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/46/15074\">",
"      Anatomy of the neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=related_link\">",
"      Patient information: Neck fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=related_link\">",
"      Patient information: Neck pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=related_link\">",
"      Patient information: Neck pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_45_17107="Dexpanthenol: Patient drug information";
var content_f16_45_17107=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dexpanthenol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/43/36530?source=see_link\">",
"     see \"Dexpanthenol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get the bowels moving after surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dexpanthenol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11652 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17107=[""].join("\n");
var outline_f16_45_17107=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030546\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030545\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030549\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030550\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030552\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030548\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030553\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030554\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/43/36530?source=related_link\">",
"      Dexpanthenol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_45_17108="Methscopolamine: Drug information";
var content_f16_45_17108=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methscopolamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/15/6388?source=see_link\">",
"    see \"Methscopolamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pamine&reg;;",
"     </li>",
"     <li>",
"      Pamine&reg; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pamine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Peptic ulcer (adjunctive):",
"     </b>",
"     Oral: 2.5 mg 30 minutes before meals or food and 2.5-5 mg at bedtime; may increase dose to 5 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as bromide: 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pamine&reg;: 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as bromide [dose-pack]: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pamine&reg; Forte: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F194794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 30 minutes before meals or food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the treatment of peptic ulcer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3263363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pamine [U.S., Canada] may be confused with Pemine brand name for penicillamine [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, insomnia, flushing, nervousness, drowsiness, dizziness, confusion, fever, CNS stimulation may be produced with large doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dry skin, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Lactation suppressed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, xerostomia, dry throat, dysphagia, nausea, vomiting, loss of taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cycloplegia, ocular tension increased, pupil dilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dry nose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis decreased, hypersensitivity reactions, anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methscopolamine, any component of the formulation, or related drugs; reflux esophagitis; glaucoma; obstructed uropathy; obstructed disease of the GI tract (pyloroduodenal stenosis); paralytic ileus; intestinal atony of elderly or debilitated individuals; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon; complicated ulcerative colitis; myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: May be a sign of incomplete intestinal obstruction, treatment should be discontinued if this occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, tachyarrhythmias, heart failure, or hypertension; evaluate tachycardia prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Use with caution in patients with autonomic neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia: Use with caution in patients with prostatic hyperplasia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with ulcerative colitis; may precipitate/aggravate toxic megacolon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; increased risk for anticholinergic effects, confusion, and hallucinations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F194800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Methscopolamine is a derivative of scopolamine. Scopolamine is reported to cross the placenta; fetal toxicity noted in case reports.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F194801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergics may suppress lactation.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F194802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 30 minutes before meals or food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F194799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methscopolamine Bromide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $270.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $237.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pamine Forte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $331.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pamine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $412.70",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F194803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pamine (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methscopolamine is a peripheral anticholinergic agent with limited ability to cross the blood-brain barrier and provides a peripheral blockade of muscarinic receptors. This agent reduces the volume and the total acid content of gastric secretions, inhibits salivation, and reduces gastrointestinal motility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Bile, urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/45/17108/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10151 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17108=[""].join("\n");
var outline_f16_45_17108=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194809\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194810\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194822\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194813\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194814\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194792\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194780\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194794\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194793\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3263363\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194820\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194797\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194784\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299692\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194789\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194790\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194800\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194816\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194801\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194802\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194799\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194803\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194783\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194796\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/15/6388?source=related_link\">",
"      Methscopolamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_45_17109="Desloratadine and pseudoephedrine: Patient drug information";
var content_f16_45_17109=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Desloratadine and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/63/25589?source=see_link\">",
"     see \"Desloratadine and pseudoephedrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clarinex-D&reg; 12 Hour;",
"     </li>",
"     <li>",
"      Clarinex-D&reg; 24 Hour [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701909",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to desloratadine, loratadine, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Trouble passing urine, glaucoma, very bad heart disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11345 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-30319E2B35-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17109=[""].join("\n");
var outline_f16_45_17109=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157767\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018885\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018887\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018886\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018891\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018892\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018894\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018889\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018890\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018895\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018896\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/63/25589?source=related_link\">",
"      Desloratadine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_45_17110="Meningitis belt map";
var content_f16_45_17110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Areas of Africa with frequent epidemics of meningococcal meningitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cohn A, Jackson ML. Meningococcal Disease. In: The Yellow Book. CDC Health Information for International Travel, 2010. Available at:",
"     <a href=\"file://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/meningococcal-disease.htm\" target=\"_blank\">",
"      file://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/meningococcal-disease.htm",
"     </a>",
"     (Accessed June 24, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17110=[""].join("\n");
var outline_f16_45_17110=null;
var title_f16_45_17111="Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy";
var content_f16_45_17111=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17111/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17111/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17111/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17111/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17111/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17111/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/45/17111/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fabry disease (also called angiokeratoma corporis diffusum, ceramide trihexosidosis, and Anderson-Fabry disease) is an X-linked glycolipid storage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/1\">",
"     1",
"    </a>",
"    ]. It is caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, resulting in the accumulation and subsequent tissue deposition of globotriaosylceramide, the glycolipid substrate for alpha-galactosidase A.",
"   </p>",
"   <p>",
"    Numerous mutations have been found in the alpha-galactosidase A gene on the long arm of the X chromosome (Xq22) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/2\">",
"     2",
"    </a>",
"    ]. While Fabry disease has been described as an X-linked recessive disorder, affected women are increasingly recognized, suggesting X-linked dominant transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations usually are evident by 10 years of age. Initial manifestations typically include neuropathy and skin lesions (",
"    <a class=\"graphic graphic_picture graphicRef81624 \" href=\"UTD.htm?37/29/38353\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71039 \" href=\"UTD.htm?33/11/33972\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/1\">",
"     1",
"    </a>",
"    ]. The neuropathy causes an almost constant discomfort of the hands and feet, with paroxysmal burning pains of the palms and soles, and hypohidrosis, while the characteristic cutaneous lesions known as angiokeratomas present as angioectatic papules that develop in the groin, hips, and umbilical region. There is also a distinctive but asymptomatic corneal dystrophy.",
"   </p>",
"   <p>",
"    The cardiovascular features of Fabry disease, and the incidence of unexpected Fabry disease in patients with otherwise unexplained left ventricular hypertrophy (LVH), will be reviewed here. The general clinical manifestations and treatment are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=see_link\">",
"     \"Clinical features and diagnosis of Fabry disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=see_link\">",
"     \"Treatment of Fabry disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As patients age, cardiac and renal disease and stroke become increasingly important. Cardiac involvement may lead to ventricular hypertrophy, conduction defects, coronary artery disease, aortic and mitral valve insufficiency, and aortic root dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These changes are typically detected by echocardiography and an electrocardiogram.",
"   </p>",
"   <p>",
"    Symptoms attributable to cardiac involvement in patients with Fabry disease include palpitations, angina pectoris, and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As noted below, symptoms of marked heart failure are unusual, although LVH with clinical features which may mimic HCM are often prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cardiac involvement typically occurs in patients with other signs of Fabry disease, the skin lesions may be missed or misdiagnosed by physicians not experienced with Fabry disease and some mutations are associated with disease that is apparently confined to the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/6,7,9-11\">",
"     6,7,9-11",
"    </a>",
"    ]. These observations constitute the rationale for screening patients with otherwise unexplained LVH. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Screening for Fabry disease in patients with LVH'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with known Fabry disease, tissue Doppler imaging can provide a preclinical diagnosis of cardiac involvement, even in patients without LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/12\">",
"     12",
"    </a>",
"    ]. Among patients with Fabry disease limited clinically to the heart, the diagnosis is typically made by the demonstration of a low plasma alpha-galactosidase A concentration or by endomyocardial biopsy, which reveals concentric lamellar bodies in the sarcoplasm of myocardial cells on electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as described in the next section, echocardiography may be associated with features specific to Fabry disease in patients with LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy (LVH) is a relatively early finding in Fabry disease that generally correlates with the severity of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. Among patients with disease that is limited to the myocardium, LVH may be the only manifestation of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The cause of the LVH is uncertain because the lysosomal deposits may comprise as little as 1 percent of the increase in ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/10,15\">",
"     10,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in wall thickness may mimic hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], although the hypertrophy is usually symmetric, not asymmetric as in hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/3,6-8\">",
"     3,6-8",
"    </a>",
"    ]. Both systolic and diastolic function are usually well preserved, and symptoms of marked heart failure are unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]. As with other manifestations of Fabry disease, men have a greater increase in left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/14\">",
"     14",
"    </a>",
"    ] and are more likely than women to have LVH (61 versus 18 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiography may be able to distinguish patients with Fabry disease from those with other causes of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. This was suggested in a report of 40 patients with Fabry disease (33 with LVH), 40 with hypertrophic cardiomyopathy, 40 with LVH due to hypertension, and 40 matched controls without LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/13\">",
"     13",
"    </a>",
"    ]. Echocardiograms of all patients were interpreted by two readers unaware of the clinical diagnosis and were correlated with findings on histologic examination (",
"    <a class=\"graphic graphic_figure graphicRef55283 \" href=\"UTD.htm?8/61/9175\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thickened hyperechogenic layer, which represented intracellular glycolipid deposition in the endocardium and the subendocardial myocardium",
"     </li>",
"     <li>",
"      A hypoechogenic layer that paralleled the hyperechogenic layer all along the ventricular contour, which represented either the mildly affected midwall myocardium or possibly a shadowing artifact due to the intracellular lipid-rich layer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This echocardiographic pattern was present in 94 percent of Fabry patients with LVH, in no Fabry patient without LVH, and in none of the other patients (100 percent specific). This is the first report of this finding in Fabry disease, and the high diagnostic accuracy needs to be confirmed in additional studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Angina and coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as one-half of patients with Fabry disease complain of anginal-type chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/8,17,18\">",
"     8,17,18",
"    </a>",
"    ]. However, coronary arteriography is normal in most patients and, when fixed lesions do occur, the patient usually has other coronary risk actors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]. Electrocardiographic features suggestive of myocardial infarction may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] but is not necessarily accompanied by myocardial necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/20\">",
"     20",
"    </a>",
"    ]. These observations have led to the suggestion that endothelial dysfunction induced by globotriaosylceramide deposition may be responsible for the ischemic manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/5,21\">",
"     5,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Arrhythmias and conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias can occur in Fabry disease. The type and frequency was evaluated in a report of 78 consecutive patients from a single referral center (mean age 44 years), 60 of whom underwent 24 hour ambulatory monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/22\">",
"     22",
"    </a>",
"    ]. Paroxysmal or persistent atrial fibrillation was present in 11 patients and nonsustained ventricular tachycardia in five. During follow-up, there was one sudden death, four patients required a pacemaker for bradyarrhythmia, one received a biventricular pacemaker, and one received an implantable cardioverter-defibrillator.",
"   </p>",
"   <p>",
"    Lipid deposits can occur throughout the conducting system (atrioventricular node, His bundle, and bundle branches) in patients with Fabry disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. Among the abnormalities that may be seen on the electrocardiogram (ECG), in addition to signs of LVH, are a short PR interval and prolongation of the QRS complex, often with a right bundle branch block pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. Other ECG findings include evidence of atrial enlargement, myocardial infarction, supraventricular tachycardia, and ventricular premature beats",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of both the aortic and, to a lesser degree, the mitral valve occurs in approximately one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/8\">",
"     8",
"    </a>",
"    ]. The valvular changes are usually associated with minor to mild degrees of regurgitation that result from marked accumulation of globotriaosylceramide in valvular tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/24\">",
"     24",
"    </a>",
"    ]. Initial reports suggested an association with mitral valve prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/14\">",
"     14",
"    </a>",
"    ] that was not confirmed in a later study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/8\">",
"     8",
"    </a>",
"    ]. The later stages of the disease can be associated with marked aortic root dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. The requirement of valve replacement for severe valvular disease is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Importance of gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected males typically have more severe abnormalities that occur at an earlier age than heterozygous females [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/4\">",
"     4",
"    </a>",
"    ]. However, expression of the clinical phenotype varies in heterozygous female carriers, with some females exhibiting severe signs of the disease because of random X-chromosome inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence of cardiac manifestations in women carrying the gene was illustrated in a review of 55 heterozygous females from a single referral center (mean age 40 years). In this cohort, 42 women were identified through screening of the family members of affected males, and 13 presented with symptoms of Fabry disease. Echocardiography revealed left ventricular hypertrophy (LVH) in 35 (64 percent), while only 13 (24 percent) had normal left ventricular mass and geometry [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings have been noted with renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. In a review of 42 patients with Fabry disease who initiated dialysis in the United States between 1995 and 1998, five (12 percent) were female; a similar percentage of females was noted among 83 European patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/25\">",
"     25",
"    </a>",
"    ]. Female carriers also can develop stroke and may have a reduced life span of as much as 15 years compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EFFICACY OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the diagnosis of Fabry disease has become particularly important because of the availability of enzyme replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. In a randomized trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/34/8741?source=see_link\">",
"     agalsidase beta",
"    </a>",
"    therapy resulted in greater clearance of microvascular endothelial deposits of globotriaosylceramide in the heart and kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=see_link\">",
"     \"Treatment of Fabry disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased enzyme activity can also lead to improved cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/11,29,30\">",
"     11,29,30",
"    </a>",
"    ]. In an initial case report of a patient considered for heart transplantation, every other day intravenous infusions of galactose, which enhances residual alpha-galactosidase A activity, led to an increase in left ventricular ejection fraction from 31 to 55 percent after two years of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/11\">",
"     11",
"    </a>",
"    ]. Preliminary evidence suggests that enzyme replacement therapy can reduce LVH and enhance regional myocardial function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SCREENING FOR FABRY DISEASE IN PATIENTS WITH LVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, atypical Fabry disease can present with left ventricular hypertrophy (LVH) and no other obvious disease manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/4,6,7,31\">",
"     4,6,7,31",
"    </a>",
"    ]. Such patients usually have concentric as opposed to asymmetric LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/3,7,8,32\">",
"     3,7,8,32",
"    </a>",
"    ], and do not have another explanation for hypertrophy (eg, hypertension or aortic valve disease). There may be a family history of premature renal, neurological, cardiovascular or skin problems, potentially attributable to unrecognized Fabry disease.",
"   </p>",
"   <p>",
"    Plasma or leukocyte alpha-galactosidase A activity is usually low but detectable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], in contrast to patients with the classic Fabry phenotype who may have undetectable activity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of some alpha-galactosidase A activity may prevent the microvascular accumulation of globotriaosylceramide that is responsible for the classic extracardiac manifestations of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of Fabry disease in patients with LVH is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial report evaluated 230 male patients who were referred for cardiac evaluation and found to have LVH [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/6\">",
"       6",
"      </a>",
"      ]. Among the 58 patients with no apparent cause of LVH, six had low plasma alpha-galactosidase A activity (&lt;1.2",
"      <span class=\"nowrap\">",
"       nanomol/mL",
"      </span>",
"      per h). One additional patient with hypertension also had a low plasma alpha-galactosidase A activity. Endomyocardial biopsy in five of these seven patients revealed the classic changes of Fabry disease. The incidence of Fabry disease was 3 percent overall (7 of 230), and 10.3 percent (6 of 58) in those without hypertension, asymmetric hypertrophy, or aortic valve disease.",
"     </li>",
"     <li>",
"      Among 153 men with a clinical diagnosis of hypertrophic cardiomyopathy, low alpha-galactosidase A activity and an alpha-galactosidase A mutation were noted in five patients with late-onset disease (age &ge;40 at diagnosis) and one with early-onset disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/7\">",
"       7",
"      </a>",
"      ]. The incidence of Fabry disease was 3.9 percent overall (6 of 153), and 6.3 percent (5 of 79) in patients with late-onset disease. Only one patient had asymmetric hypertrophy.",
"     </li>",
"     <li>",
"      In a series of 34 women with unexplained LVH, low alpha-galactosidase A activity, histologic evidence of Fabry disease, and an alpha-galactosidase A mutation were detected in four patients (12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of Fabry disease was lower in an unselected population from the Framingham Heart Study [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/31\">",
"       31",
"      </a>",
"      ]. Among 1862 unrelated participants, 50 had unexplained LVH. Among these patients, one (2 percent) had an alpha-galactosidase mutation. In contrast, eight patients (16 percent) had a mutation in a sarcomere protein gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fabry disease appears to be less common in patients with asymmetric hypertrophy. In a series of 100 consecutive patients with obstructive hypertrophic cardiomyopathy who underwent ventricular septal myectomy, no patient had the characteristic finding of Fabry disease on electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/32\">",
"     32",
"    </a>",
"    ]. Furthermore, only one patient in the above studies had left ventricular outflow tract obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17111/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of cardiovascular manifestations can develop in patients with Fabry disease, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular hypertrophy, which is the most common and usually the earliest finding. In rare cases, LVH may be the only manifestation of Fabry disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Left ventricular hypertrophy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Screening for Fabry disease in patients with LVH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conduction abnormalities and arrhythmias. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Arrhythmias and conduction abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aortic and mitral valves are often affected, but the magnitude of valvular dysfunction is usually mild. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Valvular disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms of cardiac involvement include dyspnea and angina, although obstructive coronary artery disease is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the availability of effective therapy for Fabry disease, we suggest screening for Fabry disease by measurement of plasma alpha-galactosidase A in patients with unexplained concentric LVH. (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Screening for Fabry disease in patients with LVH'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Screening for Fabry should be particularly considered in the following subgroups of patients with LVH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who also have a binary appearance of the LV endocardial border (",
"      <a class=\"graphic graphic_figure graphicRef55283 \" href=\"UTD.htm?8/61/9175\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Left ventricular hypertrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who have hypertrophic cardiomyopathy, particularly if symmetric, those with either no family history of hypertrophic cardiomyopathy or a family history consistent with X-linked disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients found to have Fabry disease, issues related to screening of first-degree relatives are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=see_link&amp;anchor=H6526096#H6526096\">",
"     \"Clinical features and diagnosis of Fabry disease\", section on 'Evaluation of family members'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the treatment of patients with Fabry disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=see_link\">",
"     \"Treatment of Fabry disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history and prognosis of patients with Fabry disease who have LVH and no other clinical manifestations is not established. Thus, it is uncertain when to initiate enzyme replacement in this setting. Such patients should undergo periodic echocardiography and we suggest the initiation of treatment when signs of progressive disease are seen (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=see_link\">",
"     \"Clinical features and diagnosis of Fabry disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=see_link\">",
"     \"Treatment of Fabry disease\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/1\">",
"      Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/2\">",
"      Eng CM, Ashley GA, Burgert TS, et al. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997; 3:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/3\">",
"      Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002; 40:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/4\">",
"      Nagueh SF. Fabry disease. Heart 2003; 89:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/5\">",
"      Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002; 13 Suppl 2:S147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/6\">",
"      Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/7\">",
"      Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/8\">",
"      Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/9\">",
"      von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/10\">",
"      Elleder M, Bradov&aacute; V, Sm&iacute;d F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990; 417:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/11\">",
"      Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001; 345:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/12\">",
"      Pieroni M, Chimenti C, Ricci R, et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/13\">",
"      Pieroni M, Chimenti C, De Cobelli F, et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006; 47:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/14\">",
"      Goldman ME, Cantor R, Schwartz MF, et al. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986; 7:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/15\">",
"      Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006; 8:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/16\">",
"      Hoign&eacute; P, Attenhofer Jost CH, Duru F, et al. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. Int J Cardiol 2006; 111:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/17\">",
"      MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/18\">",
"      MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/19\">",
"      Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. Am Heart J 1977; 93:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/20\">",
"      Becker AE, Schoorl R, Balk AG, van der Heide RM. Cardiac manifestations of Fabry's disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 1975; 36:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/21\">",
"      Barbey F, Brakch N, Linhart A, et al. Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr Suppl 2006; 95:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/22\">",
"      Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/23\">",
"      Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol 1994; 74:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/24\">",
"      Desnick RJ, Blieden LC, Sharp HL, et al. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 1976; 54:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/25\">",
"      Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/26\">",
"      Agalsidase beta (Fabrazyme) for Fabry disease. Med Lett Drugs Ther 2003; 45:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/27\">",
"      Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med 2001; 345:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/28\">",
"      Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/29\">",
"      Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/30\">",
"      Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004; 66:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/31\">",
"      Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006; 113:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/32\">",
"      Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 2003; 89:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17111/abstract/33\">",
"      Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110:1047.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4914 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17111=[""].join("\n");
var outline_f16_45_17111=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIOVASCULAR MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Angina and coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Arrhythmias and conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Valvular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Importance of gender",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EFFICACY OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SCREENING FOR FABRY DISEASE IN PATIENTS WITH LVH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4914\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4914|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/61/9175\" title=\"figure 1\">",
"      Echo in Fabry disease with LVH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4914|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/29/38353\" title=\"picture 1\">",
"      Angiokeratomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/11/33972\" title=\"picture 2\">",
"      Elevated papules",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=related_link\">",
"      Clinical features and diagnosis of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=related_link\">",
"      Treatment of Fabry disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_45_17112="Panniculitis: Recognition and diagnosis";
var content_f16_45_17112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Panniculitis: Recognition and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17112/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17112/contributors\">",
"     Lela Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17112/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17112/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17112/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17112/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/45/17112/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15212531\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panniculitis (inflammation of the subcutaneous fat) is a relatively uncommon condition that usually presents with inflammatory nodules or plaques. A wide variety of subtypes of panniculitis exist, including panniculitides related to infection, external insults, malignancy, and inflammatory diseases (",
"    <a class=\"graphic graphic_table graphicRef85714 \" href=\"UTD.htm?1/4/1101\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis of panniculitis can be challenging because different forms of panniculitis may present with similar clinical findings and many types of panniculitis are rare. A careful clinical assessment that includes an evaluation of patient risk factors, lesion distribution, and associated clinical findings (eg, ulceration, sclerosis, atrophy) can provide valuable clues for diagnosis.",
"   </p>",
"   <p>",
"    Although histopathologic examination of the affected area can be of benefit, interpretation of the biopsy findings must be approached with discretion. In the absence of careful clinical correlation and thorough consideration of the clinical and pathologic differential diagnoses, an incorrect diagnosis may be selected.",
"   </p>",
"   <p>",
"    The approach to the recognition and diagnosis of panniculitis will be discussed here. The clinical features and management of specific forms of panniculitis are reviewed in greater detail separately. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2491147\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term panniculitis refers to a group of inflammatory disorders in which the primary site of inflammation is in the subcutaneous fat. In contrast, inflammatory disorders that mainly involve the overlying dermis or underlying fascia and incidentally extend into the nearby subcutaneous fat are not considered types of panniculitis.",
"   </p>",
"   <p>",
"    The nomenclature of the panniculitides has been inconsistent and a potential source of confusion. For example, stasis panniculitis, lipodermatosclerosis, sclerosing panniculitis, hypodermitis sclerodermiformis, and chronic panniculitis with lipomembranous changes are synonymous terms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other cases, one name has been given to multiple different conditions. Weber-Christian disease, which was once thought to be a distinct entity, appears to have been an overly inclusive term applied to multiple disorders, including alpha-1-antitrypsin deficiency panniculitis, pancreatic panniculitis, factitial panniculitis, lymphoma panniculitis, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/1\">",
"     1",
"    </a>",
"    ]. With improved ability to identify these conditions, the term &ldquo;Weber-Christian disease&rdquo; has largely been abandoned by dermatologists in favor of the more specific diagnoses. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15212538\">",
"    <span class=\"h1\">",
"     SUGGESTIVE FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspicion for panniculitis typically first arises from the physical examination. Although the visible findings may be limited to a nonspecific area of erythema, palpation of an affected area reveals the deep-seated nodules and plaques characteristic of an inflammatory process located beneath the dermis. Depending on the type of panniculitis, additional features such as ulceration, atrophy, or sclerosis may also be detected. Associated tenderness is common, but is not always present.",
"   </p>",
"   <p>",
"    However, deep inflammatory nodules and plaques are not exclusive to panniculitis, and based upon the clinical scenario, disorders involving the deep dermis or fascia may need to be considered. For example, plaque morphea involving the deep dermis and eosinophilic fasciitis may be difficult to distinguish from deep morphea, which may present with true panniculitis (",
"    <a class=\"graphic graphic_picture graphicRef77587 \" href=\"UTD.htm?27/57/28561\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/133?source=see_link&amp;anchor=H16539063#H16539063\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8360?source=see_link&amp;anchor=H3#H3\">",
"     \"Eosinophilic fasciitis\", section on 'Cutaneous'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, benign and malignant tumors can manifest as subcutaneous nodules. If incidental inflammation is also present, it may be difficult to clinically distinguish these tumors from panniculitides. Nodules associated with deep bruising may also be mistaken for panniculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2491311\">",
"    <span class=\"h1\">",
"     SUBTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once panniculitis is suspected, the clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histopathological evaluation will help to confirm the presence of panniculitis and to identify the subtype of panniculitis, thereby allowing for proper patient management. Most panniculitides can be placed in one of several etiologic categories. These categories are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Inflammatory",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Infection",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Trauma",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Deposition",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Enzymatic destruction",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Malignancy",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definitive information about the relative frequency of panniculitides is not available, but there is general agreement that erythema nodosum is the most common form of panniculitis. Stasis panniculitis is likely an underappreciated, but relatively common phenomenon. Other panniculitides that, while not common, are seen on occasion in a general dermatology practice include traumatic panniculitis, lupus panniculitis, erythema induratum, cutaneous polyarteritis nodosa, subcutaneous granuloma annulare, subcutaneous sarcoidosis, and factitial panniculitis. Select examples of panniculitides in each etiologic category are described below; a more extensive list is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef85714 \" href=\"UTD.htm?1/4/1101\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122269\">",
"    <span class=\"h2\">",
"     Inflammatory disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Erythema nodosum",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Erythema nodosum occurs most often in young women and typically presents as crops of painful nodules on the shins (",
"      <a class=\"graphic graphic_picture graphicRef76621 graphicRef55744 \" href=\"UTD.htm?37/11/38072\">",
"       picture 2A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Nodules may also occur on the thighs and forearms. In contrast to many other types of panniculitis, ulceration is rare. Associated arthralgias, fever, and malaise are not uncommon.",
"      <br/>",
"      <br/>",
"      Histopathologic examination reveals a septal panniculitis with a primarily lymphocytic or mixed inflammatory infiltrate and thickened septa. Histiocytes surrounding a banana-shaped cleft (Miescher&rsquo;s radial granulomas) may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link\">",
"       \"Erythema nodosum\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Erythema nodosum usually lasts a few weeks and resolves spontaneously, but may recur. No cause is found in many cases. Infections, inflammatory bowel disease, sarcoidosis, oral contraceptives, pregnancy, and multiple other factors have been associated with erythema nodosum (",
"      <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"       table 2",
"      </a>",
"      ). Streptococcal pharyngitis is the most common identifiable cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link&amp;anchor=H11#H11\">",
"       \"Erythema nodosum\", section on 'Causes of erythema nodosum'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Lipodermatosclerosis/sclerosing",
"       </strong>",
"      </span>",
"      panniculitis",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Lipodermatosclerosis, also known as sclerosing panniculitis, is a form of panniculitis that usually occurs in the setting of venous insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Indurated plaques with associated erythema, edema, and hyperpigmentation on one or both lower legs (often on the medial aspect) are characteristic and result from the fibrosis and atrophy of subcutaneous fat (",
"      <a class=\"graphic graphic_picture graphicRef65447 graphicRef85713 \" href=\"UTD.htm?28/9/28823\">",
"       picture 3A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ]. On the legs, the sclerosis may have an appearance that is reminiscent of an inverted wine bottle or piano leg. Lipodermatosclerosis can also occur in other areas of stasis, such as the abdominal pannus or breasts.",
"      <br/>",
"      <br/>",
"      Histopathologic findings in lipodermatosclerosis include overlying features of stasis dermatitis and findings at the level of the subcutaneous fat vary based upon the stage of the disease. Late stage lesions demonstrate thickened, fibrotic septa, extensive fat atrophy, and an inflammatory infiltrate composed of lymphocytes, histiocytes, and foamy macrophages [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ]. Lipomembranous change (eosinophilic material lining fat pseudocyst) is frequently present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical evaluation of lower extremity chronic venous disease\", section on 'Lipodermatosclerosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lupus panniculitis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Lupus panniculitis (also known as lupus profundus) is an uncommon form of panniculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ]. Affected patients typically develop erythematous nodules in sites that are often spared in other panniculitides, including the upper arms, shoulders, face, scalp, and buttocks (",
"      <a class=\"graphic graphic_picture graphicRef85711 graphicRef85712 graphicRef83791 \" href=\"UTD.htm?36/57/37784\">",
"       picture 4A-C",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. There may be concurrent, overlying lesions of discoid lupus erythematosus. Systemic lupus erythematosus is present in a minority of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H13#H13\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Lupus profundus (lupus erythematosus panniculitis)'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Histopathologic examination reveals a lobular lymphocytic panniculitis that often demonstrates lymphoid follicles. Overlying histopathologic features of discoid lupus may be present. Direct immunofluorescence of the skin is often positive with linear deposition of IgM and C3 at the dermal-epidermal junction, but is not usually necessary for diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ]. Disfiguring lipoatrophy frequently occurs in sites of regressed lesions (",
"      <a class=\"graphic graphic_picture graphicRef85711 graphicRef85712 graphicRef83791 \" href=\"UTD.htm?36/57/37784\">",
"       picture 4A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Cutaneous polyarteritis nodosa &ndash;",
"      </strong>",
"      Cutaneous polyarteritis nodosa is a primary form of vasculitis involving the vessels in the septae of the subcutaneous fat. A more accurate term for this variant may be &ldquo;primarily cutaneous polyarteritis nodosa,&rdquo; since internal organ involvement may also occur. Patients typically present with tender subcutaneous nodules that often ulcerate and associated livedo racemosa (",
"      <a class=\"graphic graphic_picture graphicRef75391 graphicRef64023 \" href=\"UTD.htm?0/0/11\">",
"       picture 5A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/9\">",
"       9",
"      </a>",
"      ]. Low-grade systemic symptoms (arthralgias, myalgias, malaise, and fatigue) may also be present [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Examination of pathology specimens from early lesions reveals neutrophilic vasculitis of arteries and arterioles in the subcutaneous septa (",
"      <a class=\"graphic graphic_picture graphicRef51874 \" href=\"UTD.htm?9/32/9737\">",
"       picture 6",
"      </a>",
"      ). The inflammatory infiltrate transitions to a predominantly lymphohistiocytic infiltrate over time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/10\">",
"       10",
"      </a>",
"      ]. The disease often follows a chronic course that may be characterized by periods of exacerbations and clinical remissions. Examples of disorders that have been associated with cutaneous polyarteritis nodosa include streptococcal infection, inflammatory bowel disease, and hepatitis B and C [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema induratum",
"      </strong>",
"      &ndash; Erythema induratum typically occurs in young to middle-aged women, and usually presents as nodules on the posterior lower legs (",
"      <a class=\"graphic graphic_picture graphicRef64335 graphicRef53596 graphicRef76526 \" href=\"UTD.htm?39/30/40424\">",
"       picture 7A-C",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/11\">",
"       11",
"      </a>",
"      ]. Unlike erythema nodosum, ulceration is common. Although there is a well-established association with tuberculosis, erythema induratum can be idiopathic or associated with other infections or drugs. The terms erythema induratum and nodular vasculitis have been used synonymously by some authors. Others reserve the term &ldquo;nodular vasculitis&rdquo; for cases unassociated with tuberculosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=see_link&amp;anchor=H22503432#H22503432\">",
"       \"Cutaneous manifestations of tuberculosis\", section on 'Erythema induratum of Bazin'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122336\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Infectious panniculitis &ndash;",
"      </strong>",
"      Infectious panniculitis usually presents as a primarily lobular panniculitis that may be caused by bacterial, mycobacterial, fungal, protozoal, or viral infections [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/12\">",
"       12",
"      </a>",
"      ]. It may occur as a result of hematogenous dissemination of microorganisms, direct extension from a nearby focus of infection, or direct inoculation. The appearance of the lesions is dependent on the underlying cause and the severity of infection, ranging from indolent nodules to acute fluctuant abscesses. Immunosuppressed individuals are at increased risk for infectious panniculitis. Microbial cultures and histopathologic stains are useful for diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2492411\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Traumatic panniculitis &ndash;",
"      </strong>",
"      Panniculitis can occur at the site of blunt injury [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/13\">",
"       13",
"      </a>",
"      ]. For example, minor trauma to the shins can result in the development of tender subcutaneous nodules [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ]. Histopathologic examination reveals cystic spaces within the fat, variable fibrosis and hemorrhage, and a peripheral lymphohistiocytic inflammatory infiltrate [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cold panniculitis &ndash;",
"      </strong>",
"      Cold panniculitis may occur in any age group, but occurs most often in very young children, in whom it is sometimes called &ldquo;popsicle panniculitis.&rdquo; Patients present with erythematous nodules and plaques at the site of cold injury (",
"      <a class=\"graphic graphic_picture graphicRef83785 graphicRef83786 \" href=\"UTD.htm?31/32/32264\">",
"       picture 8A-B",
"      </a>",
"      ). The cheeks are a common site of involvement. Spontaneous resolution typically occurs within a few weeks. Histopathologic findings include a primarily lobular lymphohistiocytic infiltrate [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Factitial panniculitis &ndash;",
"      </strong>",
"      Factitial panniculitis is a form of panniculitis that results from the injection of foreign substances into the subcutaneous fat [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/15\">",
"       15",
"      </a>",
"      ]. Factitial panniculitis should be considered when lesions are in atypical locations or have unusual shapes. Although some cases result from the injection of medical therapies, other cases result from the inappropriate injection of substances for cosmetic purposes (eg, paraffin), or the injection of harmful substances (eg, urine, feces, foods, or chemicals) by patients with emotional disturbances or psychiatric disorders. It is common for patients who deliberately inject harmful substances to deny self-injection.",
"      <br/>",
"      <br/>",
"      The clinical manifestations vary with the type and amount of substance injected. Patients may have inflammatory nodules or plaques, and abscesses may develop. The histopathologic findings are also variable. In some cases, the foreign material can be identified on pathologic sections [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2492437\">",
"    <span class=\"h2\">",
"     Deposition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Calciphylaxis &ndash;",
"      </strong>",
"      Calciphylaxis is an uncommon, life-threatening disorder that most commonly occurs in the setting of end-stage renal failure. Patients present with painful nodules and plaques associated with retiform (angulated) purpura and cutaneous necrosis (",
"      <a class=\"graphic graphic_picture graphicRef66308 \" href=\"UTD.htm?17/48/18180\">",
"       picture 9",
"      </a>",
"      ). Sites with abundant adipose tissue, such as the thighs and buttocks are frequently affected. The histopathologic findings are specific, demonstrating calcium deposits within the walls of vessels in the reticular dermis and subcutaneous fat. Necrosis of fat lobules, fat calcification, and a mixed inflammatory infiltrate are also evident. Calciphylaxis is associated with a poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=see_link\">",
"       \"Calciphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Gout &ndash;",
"      </strong>",
"      Rarely, individuals with hyperuricemia develop deposits of urate crystals in the subcutaneous fat that result in the development of erythematous, indurated subcutaneous plaques [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. The lower extremities are common sites for involvement. Histopathologic examination reveals needle-like crystals and a granulomatous inflammatory infiltrate with multinucleated giant cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gout\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2492460\">",
"    <span class=\"h2\">",
"     Enzymatic destruction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pancreatic panniculitis &ndash;",
"      </strong>",
"      Pancreatic panniculitis (also known as pancreatic fat necrosis and enzymatic panniculitis) is a rare, primarily lobular panniculitis that infrequently develops in individuals with pancreatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/18\">",
"       18",
"      </a>",
"      ]. The most common associated disorders are acute and chronic pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ]. The cause of the disorder is unknown, but a role for release of pancreatic enzymes has been considered. Tender, inflammatory nodules typically develop on the distal lower extremities, though other sites may also be affected (",
"      <a class=\"graphic graphic_picture graphicRef83789 \" href=\"UTD.htm?30/57/31634\">",
"       picture 10",
"      </a>",
"      ). The nodules may ulcerate and drain oily brown liquid derived from the necrosis of adipocytes. Acute arthritis often is present.",
"      <br/>",
"      <br/>",
"      Characteristic histopathologic findings include a primarily lobular panniculitis with extensive necrosis of adipocytes and ghost adipocytes (adipocytes without nuclei) with calcium deposits. In patients with pancreatitis, panniculitis usually resolves upon the cessation of pancreatic inflammation. However, in patients with pancreatic carcinoma, the course of panniculitis tends to be more persistent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Alpha-1 antitrypsin deficiency panniculitis &ndash;",
"      </strong>",
"      Alpha-1 antitrypsin deficiency panniculitis is a rare form of panniculitis restricted to individuals with alpha-1 antitrypsin deficiency. Trauma may precipitate lesions. Subcutaneous nodules may occur on the face, trunk, or extremities. Lesions preferentially occur on the lower trunk and thighs. Ulceration and release of oily material due to adipocyte necrosis are common.",
"      <br/>",
"      <br/>",
"      Extensive fat necrosis is typically seen on biopsy. Infiltration of neutrophils between collagen bundles (splaying of neutrophils) and a mixture of areas of normal fat adjacent to necrotic fat may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link&amp;anchor=H6#H6\">",
"       \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\", section on 'Skin disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2492480\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Subcutaneous lymphoma &ndash;",
"      </strong>",
"      Certain lymphomas, primarily those associated with a cytotoxic T-cell phenotype, and less commonly with an",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell type may present with significant involvement of the subcutaneous fat [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/20\">",
"       20",
"      </a>",
"      ]. Subcutaneous panniculitis-like T-cell lymphoma is one of these disorders. Patients typically present with painless nodules or plaques on the extremities, trunk, or face and may have accompanying B symptoms (eg, weight loss, fever, and fatigue). Histopathologic examination demonstrates an infiltrate of atypical lymphocytes within the fat lobules and cytophagocytosis (macrophages phagocytizing erythrocytes and leukocytes). The phagocytizing macrophages are also known as &ldquo;beanbag cells&rdquo;. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The term cytophagic histiocytic panniculitis has also been used to refer to subcutaneous panniculitis-like T-cell lymphoma, but cytophagic histiocytic panniculitis may also occur in the absence of malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1439585\">",
"    <span class=\"h2\">",
"     Infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain panniculitides occur exclusively or primarily in infants or children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/21\">",
"     21",
"    </a>",
"    ]. The subcutaneous fat of infants has a higher ratio of saturated to unsaturated fatty acids and a higher melting point than the subcutaneous fat of older children and adults. Lowered skin temperatures can lead to crystallization in the fat and an inflammatory reaction, and it is hypothesized that the unique properties of infantile fat contribute to the development of these disorders. The subtypes of panniculitis that exhibit a predilection for infants and children are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Subcutaneous fat necrosis of the newborn &ndash;",
"      </strong>",
"      Subcutaneous fat necrosis of the newborn is an uncommon condition that typically occurs in full-term infants during the first few weeks of life. The disorder presents as erythematous or violaceous indurated subcutaneous nodules or plaques on the cheeks, buttocks, arms, thighs, or back (",
"      <a class=\"graphic graphic_picture graphicRef83790 \" href=\"UTD.htm?17/14/17635\">",
"       picture 11",
"      </a>",
"      ). Occasionally, there is associated symptomatic hypercalcemia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/22\">",
"       22",
"      </a>",
"      ]. The nodules typically resolve spontaneously.",
"      <br/>",
"      <br/>",
"      Histopathologic examination reveals a lobular panniculitis with an inflammatory infiltrate containing macrophages and multinucleated giant cells. In addition, cells that contain radially arranged needle-like clefts that represent crystalline fat are present. Small calcium deposits may be detected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=see_link&amp;anchor=H5#H5\">",
"       \"Skin nodules in newborns and infants\", section on 'Subcutaneous fat necrosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sclerema neonatorum &ndash;",
"      </strong>",
"      Sclerema neonatorum is a rare condition that occurs most often in severely ill premature neonates. There is a diffuse, rapidly progressive hardening of the skin, and the prognosis is poor. Histopathologic examination demonstrates minimal inflammation and necrosis. The characteristic finding is cells with radially arranged needle-shaped clefts, similar to those seen in subcutaneous fat necrosis of the newborn [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cold panniculitis &ndash;",
"      </strong>",
"      Cold panniculitis occurs most often in very young children. Cold panniculitis is described above. (See",
"      <a class=\"local\" href=\"#H2492411\">",
"       'Trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Poststeroid panniculitis &ndash;",
"      </strong>",
"      Poststeroid panniculitis is a rare lobular panniculitis that has occurred in infants and children following the sudden withdrawal of high dose systemic glucocorticoids. Affected children develop erythematous nodules 1 to 10 days after glucocorticoid withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/21\">",
"       21",
"      </a>",
"      ]. The cheeks are a common site of involvement.",
"      <br/>",
"      <br/>",
"      The histopathologic findings resemble subcutaneous fat necrosis of the newborn. A lymphohistiocytic infiltrate is present in the fat lobules and cells with needle-shaped clefts may be detected [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"       6",
"      </a>",
"      ]. Lesions spontaneously resolve within a few weeks to a few months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2491494\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2489745\">",
"    <span class=\"h2\">",
"     Patient history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once panniculitis is suspected, certain clinical clues assist with narrowing the differential and creating a plan for additional work-up. Recollection of the categories of conditions that can present with panniculitis can be useful (",
"    <a class=\"graphic graphic_table graphicRef85714 \" href=\"UTD.htm?1/4/1101\">",
"     table 1",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"    Examples of questions that may assist with identifying the most likely cause of panniculitis are reviewed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inflammatory &ndash;",
"      </strong>",
"      Was there a preceding streptococcal infection or other risk factors associated with erythema nodosum? Does the patient have a history of connective tissue disease or symptoms suggestive of a connective tissue disease? Does the patient have a history of chronic lower extremity edema (lipodermatosclerosis)?",
"     </li>",
"     <li>",
"      <strong>",
"       Infection &ndash;",
"      </strong>",
"      Is the patient immunosuppressed? Is the patient acutely ill?",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Trauma/stasis",
"       </strong>",
"      </span>",
"      &ndash;",
"      Is there a history of local trauma or exposure to cold? Are the lesions occurring in a site that received injections or radiation therapy?",
"     </li>",
"     <li>",
"      <strong>",
"       Deposition &ndash;",
"      </strong>",
"      Does the patient have renal failure (calciphylaxis) or gout? &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Enzymatic destruction &ndash;",
"      </strong>",
"      Are there symptoms suggestive of pancreatitis? Does the patient have early-onset emphysema (alpha-1 antitrypsin deficiency)?",
"     </li>",
"     <li>",
"      <strong>",
"       Malignancy &ndash;",
"      </strong>",
"      Is there a history of malignancy? Does the patient appear acutely or chronically ill?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2491564\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because inflammatory nodules and plaques occur in various forms of panniculitis as well as other types of disorders, diagnosing a specific form of panniculitis based only on examination of the affected area is usually difficult. The patient history and an assessment of additional clinical findings, such as ulceration, atrophy, sclerosis, and livedo reticularis can be useful for diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ulceration &ndash;",
"      </strong>",
"      Occurs in multiple forms of panniculitis, but typically absent in erythema nodosum, which assists with distinguishing this disorder from erythema induratum.",
"     </li>",
"     <li>",
"      <strong>",
"       Atrophy &ndash;",
"      </strong>",
"      Lesions",
"      <strong>",
"      </strong>",
"      of lupus panniculitis typically resolve with significant atrophy.",
"     </li>",
"     <li>",
"      <strong>",
"       Sclerosis &ndash;",
"      </strong>",
"      Lipodermatosclerosis and deep morphea present with features of sclerosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Livedo racemosa &ndash;",
"      </strong>",
"      Livedo racemosa commonly occurs in association with cutaneous polyarteritis nodosa (",
"      <a class=\"graphic graphic_picture graphicRef64023 \" href=\"UTD.htm?35/42/36512\">",
"       picture 5B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the location of lesions may also provide important diagnostic clues. Examples of preferential sites of involvement for specific panniculitides are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Erythema nodosum &ndash;",
"      </strong>",
"      anterior lower legs",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema induratum &ndash;",
"      </strong>",
"      posterior lower legs",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Lipodermatosclerosis/stasis",
"       </strong>",
"      </span>",
"      panniculitis &ndash;",
"      medial lower legs",
"     </li>",
"     <li>",
"      <strong>",
"       Alpha-1-antitrypsin deficiency panniculitis &ndash;",
"      </strong>",
"      buttocks, flanks, and thighs",
"     </li>",
"     <li>",
"      <strong>",
"       Subcutaneous sarcoidosis &ndash;",
"      </strong>",
"      forearms",
"     </li>",
"     <li>",
"      <strong>",
"       Lupus panniculitis &ndash;",
"      </strong>",
"      face, scalp, upper arms, breasts, upper trunk, buttocks, and thighs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15212571\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies can provide valuable information for diagnosis, and are indicated in cases in which the diagnosis is uncertain or to confirm the diagnosis in cases in which the clinical course of a panniculitis does not proceed as expected. Biopsies are most useful when findings characteristic of a specific form of panniculitis are identified. However, the histopathologic findings are often ambiguous. In many cases, clinical correlation and careful consideration of the differential diagnosis is required to arrive at a correct diagnosis.",
"   </p>",
"   <p>",
"    Although biopsies are usually well-tolerated, potential consequences include scarring, infection, and poor wound healing. Therefore, in situations in which the clinical evaluation yields a relatively certain diagnosis, the decision to perform a confirmatory biopsy is individualized. As an example, the benefit gained from the histologic confirmation of the diagnosis of erythema nodosum is not necessarily worth the resulting scar from deep excisional biopsy in a typical, short-lived case. Similarly, the benefit gained from histologic confirmation of lipodermatosclerosis may or may not be worth the risk of having a chronic wound on the lower leg. However, in other situations, a biopsy is critical for proper patient evaluation and management. For example, the attainment of a tissue specimen for histopathologic examination and microbial studies is essential when infectious panniculitis is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122783\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to achieve the highest diagnostic yield, the biopsy specimen must include a generous sample of the subcutaneous fat. This is best accomplished by an elliptical excision performed with a scalpel. Alternatively, a large (6 to 8 mm) punch biopsy may be performed. Elliptical excisions often result in more cosmetically-satisfactory scars. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H5#H5\">",
"     \"Skin biopsy techniques\", section on 'Biopsy techniques'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15212578\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous fat has a fairly simple structure, consisting mainly of fat cells that are organized in lobules divided by fibrous septa, together with vessels and nerves. The panniculitides are often classified based on the histologic findings, particularly the location of the pathologic process (septal versus lobular) and the presence or absence of vasculitis (",
"    <a class=\"graphic graphic_table graphicRef85715 \" href=\"UTD.htm?16/9/16540\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17112/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. To narrow the histologic differential diagnosis, the following questions are addressed during histopathologic examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the pathology primarily in the fat?",
"     </li>",
"     <li>",
"      Is the pathologic process predominantly in the septa, lobules, or both?",
"     </li>",
"     <li>",
"      Is vasculitis present?",
"     </li>",
"     <li>",
"      What types of cells comprise the inflammatory infiltrate?",
"     </li>",
"     <li>",
"      What other features are present (eg, necrosis, organisms, crystals, calcium, foreign material)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although evaluation of the pathology in the context of the clinical findings often establishes the diagnosis, there are limitations to consider during the interpretation of the biopsy findings. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The relative lack of complexity of subcutaneous tissue means that there is a relatively small number of ways the subcutaneous fat can appear histologically. Even with an optimal sample, it may not be possible to narrow the histologic differential diagnosis to one entity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammatory infiltrates are not absolutely confined to septa in septal panniculitis, and are not limited to lobules in lobular panniculitis. The fundamental distinction between a septal and a lobular panniculitis is based on the predominant location of the infiltrate. In practice, this can be a difficult distinction to make, particularly if the sample size is small.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The biopsy may not include a sufficient amount of subcutaneous fat. This is particularly likely with small punch biopsies but can also occur with excisions if the practitioner is not careful to include an adequate sample of subcutaneous fat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An inadequate biopsy or insufficient sampling of an adequate biopsy may affect the ability to detect the presence of vasculitis. For example, a biopsy that may initially appear to be erythema nodosum may be revealed to be polyarteritis nodosa when additional sections are examined. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Histologic changes evolve as lesions mature. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2491529\">",
"    <span class=\"h3\">",
"     Special studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, obtaining a diagnosis may require investigation beyond the clinical evaluation and routine histopathologic examination. When infection is in the clinical differential diagnosis, tissue cultures and histologic stains for organisms are usually indicated. If malignancy is suspected, special studies to determine cell type may be required. In cases of panniculitis where the diagnosis is not straightforward, the tissue sample should be polarized to look for foreign material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122811\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the diagnoses suspected based upon the clinical and histopathologic examinations, other tests may aid in identifying the cause of panniculitis. Examples include tests to evaluate patients for pancreatitis, tuberculosis, alpha-1 antitrypsin deficiency, and autoimmune disease. If evaluation reveals a diagnosis associated with other disorders, such as erythema nodosum (",
"    <a class=\"graphic graphic_table graphicRef70718 \" href=\"UTD.htm?35/8/35981\">",
"     table 2",
"    </a>",
"    ) or subcutaneous fat necrosis of the newborn (hypercalcemia), additional testing is performed as indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15212585\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term &ldquo;panniculitis&rdquo; is used to refer to inflammatory disorders in which the primary site of involvement is the subcutaneous fat. Many types of panniculitis have been described, including immune-mediated, infectious, trauma-induced, malignant, and other types of panniculitides (",
"      <a class=\"graphic graphic_table graphicRef85714 \" href=\"UTD.htm?1/4/1101\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2491311\">",
"       'Subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suspicion for panniculitis typically arises upon the detection of the clinical findings of one or more deep-seated inflammatory nodule or plaque. Depending on the type of panniculitis, additional features, such as ulceration, atrophy, or sclerosis may be present. (See",
"      <a class=\"local\" href=\"#H15212538\">",
"       'Suggestive features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain types of panniculitis are more likely to occur in children than adults. Examples include subcutaneous fat necrosis of the newborn and sclerema neonatorum, which typically occur in the neonatal period. Cold panniculitis and poststeroid panniculitis are also most likely to occur in children. (See",
"      <a class=\"local\" href=\"#H1439585\">",
"       'Infants and children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical history and physical examination play an important role in identifying the cause of panniculitis. The recognition of the distribution of lesions and associated clinical findings is often useful. (See",
"      <a class=\"local\" href=\"#H2489745\">",
"       'Patient history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2491564\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsies are indicated when the diagnosis is uncertain, when the attainment of a tissue specimen may yield information useful for patient management, or when the clinical course does not proceed as expected. An elliptical excision is the preferred procedure for biopsy. A large punch biopsy (6 to 8 mm) may be performed as an alternative. (See",
"      <a class=\"local\" href=\"#H15212571\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain features aid in the evaluation of a biopsy specimen. The status of panniculitis as lobular versus septal, the presence or absence of vasculitis, the nature of the inflammatory infiltrate, and the visualization of distinctive features assist with diagnosis (",
"      <a class=\"graphic graphic_table graphicRef85715 \" href=\"UTD.htm?16/9/16540\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15212578\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The limitations of histology in diagnosis must always be considered. Careful clinical correlation with biopsy findings is essential. If there is discordance between the clinical and histologic findings, or if disease fails to respond as expected to therapy, the diagnosis should be reassessed. (See",
"      <a class=\"local\" href=\"#H15212578\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Patterson JW. Panniculitis. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier Ltd, London 2008. p.1515.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/2\">",
"      Mert A, Kumbasar H, Ozaras R, et al. Erythema nodosum: an evaluation of 100 cases. Clin Exp Rheumatol 2007; 25:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/3\">",
"      Requena L, Yus ES. Erythema nodosum. Dermatol Clin 2008; 26:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/4\">",
"      Kirsner RS, Pardes JB, Eaglstein WH, Falanga V. The clinical spectrum of lipodermatosclerosis. J Am Acad Dermatol 1993; 28:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/5\">",
"      Requena C, Sanmart&iacute;n O, Requena L. Sclerosing panniculitis. Dermatol Clin 2008; 26:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/6\">",
"      Requena L, S&aacute;nchez Yus E. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol 2001; 45:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/7\">",
"      Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol 1999; 26:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/8\">",
"      Peters MS, Su WP. Lupus erythematosus panniculitis. Med Clin North Am 1989; 73:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/9\">",
"      Morgan AJ, Schwartz RA. Cutaneous polyarteritis nodosa: a comprehensive review. Int J Dermatol 2010; 49:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/10\">",
"      Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol 2001; 45:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/11\">",
"      Mascar&oacute; JM Jr, Baselga E. Erythema induratum of bazin. Dermatol Clin 2008; 26:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/12\">",
"      Delgado-Jimenez Y, Fraga J, Garc&iacute;a-D&iacute;ez A. Infective panniculitis. Dermatol Clin 2008; 26:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/13\">",
"      Moreno A, Marcoval J, Peyri J. Traumatic panniculitis. Dermatol Clin 2008; 26:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/14\">",
"      Quesada-Cort&eacute;s A, Campos-Mu&ntilde;oz L, D&iacute;az-D&iacute;az RM, Casado-Jim&eacute;nez M. Cold panniculitis. Dermatol Clin 2008; 26:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/15\">",
"      Sanmart&iacute;n O, Requena C, Requena L. Factitial panniculitis. Dermatol Clin 2008; 26:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/16\">",
"      Ochoa CD, Valderrama V, Mejia J, et al. Panniculitis: another clinical expression of gout. Rheumatol Int 2011; 31:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/17\">",
"      Snider AA, Barsky S. Gouty panniculitis: a case report and review of the literature. Cutis 2005; 76:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/18\">",
"      Garc&iacute;a-Romero D, Vanaclocha F. Pancreatic panniculitis. Dermatol Clin 2008; 26:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/19\">",
"      Valverde R, Rosales B, Ortiz-de Frutos FJ, et al. Alpha-1-antitrypsin deficiency panniculitis. Dermatol Clin 2008; 26:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/20\">",
"      Gallardo F, Pujol RM. Subcutaneous panniculitic-like T-cell lymphoma and other primary cutaneous lymphomas with prominent subcutaneous tissue involvement. Dermatol Clin 2008; 26:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/21\">",
"      Torrelo A, Hern&aacute;ndez A. Panniculitis in children. Dermatol Clin 2008; 26:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/22\">",
"      Burden AD, Krafchik BR. Subcutaneous fat necrosis of the newborn: a review of 11 cases. Pediatr Dermatol 1999; 16:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17112/abstract/23\">",
"      Diaz Cascajo C, Borghi S, Weyers W. Panniculitis: definition of terms and diagnostic strategy. Am J Dermatopathol 2000; 22:530.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13780 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-BA6E9C3E55-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17112=[""].join("\n");
var outline_f16_45_17112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15212585\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15212531\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2491147\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15212538\">",
"      SUGGESTIVE FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2491311\">",
"      SUBTYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4122269\">",
"      Inflammatory disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4122336\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2492411\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2492437\">",
"      Deposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2492460\">",
"      Enzymatic destruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2492480\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1439585\">",
"      Infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2491494\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2489745\">",
"      Patient history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2491564\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15212571\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4122783\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15212578\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2491529\">",
"      - Special studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4122811\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15212585\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13780|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/57/28561\" title=\"picture 1\">",
"      Deep morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/59/12209\" title=\"picture 2A\">",
"      Erythema nodosum - legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/29/7638\" title=\"picture 2B\">",
"      Erythema nodosum - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/14/11490\" title=\"picture 3A\">",
"      Stasis dermatitis sclerotic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/47/24306\" title=\"picture 3B\">",
"      Lipodermatosclerosis sclerotic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/51/34609\" title=\"picture 4A\">",
"      Lupus panniculitis facial lipoatrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22737\" title=\"picture 4B\">",
"      Lupus panniculitis on extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/15/1264\" title=\"picture 4C\">",
"      Lupus panniculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/21/36176\" title=\"picture 5A\">",
"      Cutaneous polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/42/36512\" title=\"picture 5B\">",
"      Livedo racemosa in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/32/9737\" title=\"picture 6\">",
"      Cutaneous polyarteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/62/44002\" title=\"picture 7A\">",
"      Erythema induratum 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/6/28768\" title=\"picture 7B\">",
"      Erythema induratum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/30/42479\" title=\"picture 7C\">",
"      Erythema induratum of Bazin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/59/18355\" title=\"picture 8A\">",
"      Cold panniculitis on cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/53/2900\" title=\"picture 8B\">",
"      Cold panniculitis on thighs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/48/18180\" title=\"picture 9\">",
"      Calciphylaxis retiform purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/57/31634\" title=\"picture 10\">",
"      Pancreatic panniculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/14/17635\" title=\"picture 11\">",
"      Subcutaneous fat necrosis of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/4/1101\" title=\"table 1\">",
"      Clinical classification of panniculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/8/35981\" title=\"table 2\">",
"      Differential dx E nodosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/9/16540\" title=\"table 3\">",
"      Histological classification of panniculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=related_link\">",
"      Clinical evaluation of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=related_link\">",
"      Cutaneous manifestations of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8360?source=related_link\">",
"      Eosinophilic fasciitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=related_link\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/133?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=related_link\">",
"      Skin nodules in newborns and infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_45_17113="Definition and diagnosis of hypertension in children and adolescents";
var content_f16_45_17113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and diagnosis of hypertension in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17113/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17113/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17113/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17113/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17113/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/45/17113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that adult hypertension (HTN) has its antecedents during childhood, as childhood blood pressure (BP) predicts adult BP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. HTN in childhood and adolescence contributes to premature atherosclerosis and the early development of cardiovascular disease (CVD). As a result, identifying children with HTN and successfully treating their HTN should have an important impact on long-term outcomes of CVD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk factors and development of atherosclerosis in childhood\", section on 'Atherosclerotic changes in childhood'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk factors and development of atherosclerosis in childhood\", section on 'Hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'Rationale for intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definition and diagnosis of HTN in children will be reviewed here. The risk factors, epidemiology, etiology, evaluation, and treatment of HTN in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link\">",
"     \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link\">",
"     \"Evaluation of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressures in children in 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/3\">",
"     3",
"    </a>",
"    ]. These guidelines were updated in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition of childhood hypertension (HTN) is based upon the normative distribution of blood pressure (BP) in healthy children. This is in contrast to adult HTN, which is primarily defined by clinical outcome data (ie, risk of cardiovascular disease and mortality) from large trials of antihypertensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. This clinical definition cannot be applied to children because cardiovascular (CV) events other than left ventricular hypertrophy do not typically occur until adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link\">",
"     \"Overview of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Body size is the most important determinant of BP in children and adolescents. Thus, classification of BP is more accurate when the values are adjusted for height as well as age and gender to avoid misclassifying children at the extremes of normal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, normative BP percentiles are based upon data on gender, age, height, and blood pressure measurements from the National Health and Nutrition Examination Survey (NHANES) and other population-based studies (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 2",
"    </a>",
"    ). The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In children, definitions based upon BP percentiles were developed by the NHBPEP Working Group to categorize BP measurements based upon the above normative data [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"     4",
"    </a>",
"    ]. In the United States, the following definitions are universally used to classify childhood BP measurements. The systolic and diastolic BPs are of equal importance; if there is a disparity between the two, the higher value determines the BP category.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal BP &ndash; Both systolic and diastolic BP &lt;90th percentile.",
"     </li>",
"     <li>",
"      Prehypertension &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;90th percentile but &lt;95th percentile",
"      <strong>",
"       or",
"      </strong>",
"      if BP exceeds",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg even if &lt;90th percentile. Prehypertension is predictive of hypertension. This was illustrated in one study based upon the National Childhood Blood Pressure database that demonstrated 14 percent of male and 12 percent female adolescents were hypertensive two years later [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertension &ndash; HTN is defined as either systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;95th percentile measured upon three or more occasions. The degree of HTN is further delineated by the two following stages:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Stage 1 hypertension",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP between the 95th percentile and 5 mmHg above the 99th percentile.",
"     </li>",
"     <li>",
"      <strong>",
"       Stage 2 hypertension",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99th percentile plus 5 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision process for evaluation and treatment varies with the severity of the HTN. As noted above, the NHBPEP recommendation defines two stages for HTN [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"     4",
"    </a>",
"    ]. Stage 2 identifies those children who need more prompt evaluation and immediate pharmacologic treatment, while stage 1 HTN allows for more time for evaluation and initial treatment with nonpharmacologic therapy unless the patient is symptomatic or has hypertensive target-organ damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The above definitions apply only to persistent HTN. With an acute elevation of BP, as can occur in acute glomerulonephritis, acute renal failure, pheochromocytoma, or preeclampsia, it is the magnitude and the rate of increase above baseline that determines the risk of serious morbidity and, at times, mortality. In these settings, malignant HTN can develop at absolute BPs that might otherwise be considered to represent mild or moderate HTN in other patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H2#H2\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Mechanisms of vascular injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limitation to using percentiles derived from study populations to define normal BP is the need to account for secular trends [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/8\">",
"     8",
"    </a>",
"    ], which may vary among countries as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean SBP increased by 1.3 mmHg and the mean DBP increased by 8.4 between 1988 to 1994 and 1999 to 2002, respectively, in part due to the increased prevalence of overweight and obese children [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link\">",
"       \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, there was a decrease in both systolic (range of decrease 7.7 to 10 mmHg) and diastolic (range of decrease 8.8 to 11 mmHg) BPs in two representative cohorts of adolescents from Northern Ireland over a 10-year period from two study periods of 1989 to 1990 and of 1999 to 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/10\">",
"       10",
"      </a>",
"      ]. The findings in the Irish study were independent of body composition or birth weight.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the normative BP percentiles are based upon data that includes all children regardless of their BMI. The increase in obesity prevalence results in an overall increase in childhood blood pressure. It has been proposed that in order for normative BP values to be truly representative they should be based upon BP values obtained only from children with normal weight (ie, BMI &lt;85th percentile) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/11\">",
"     11",
"    </a>",
"    ]. As a result, BP percentiles were developed using the databases from the NHANES surveys from 1963 through 1994 excluding values from children with BMI &ge;85th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/11\">",
"     11",
"    </a>",
"    ]. Using this approach, the prehypertension and hypertension threshold values are slightly lower than those of the 2004 NHBPEP. Whether using BP percentiles based upon normal-weight children is a better method of identifying prehypertension and hypertension children remains an open question requiring further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In other countries, several studies have collected data to define normative blood pressure for children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in Great Britain, reference range BP percentiles for children and young adults between 4 and 23 years of age were based upon demographic data obtained from seven national surveys that recorded three blood pressure measurements using an oscillometric device (Dinamapp 8100) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/14\">",
"     14",
"    </a>",
"    ]. High blood pressure for age was defined as either systolic or diastolic blood pressures above the 98th percentile for age and high-normal blood pressure as blood pressure between the 91st and 98th percentile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the diagnosis of persistent childhood hypertension (HTN) is made when repeat blood pressure (BP) values on",
"    <strong>",
"     three",
"    </strong>",
"    separate visits are greater than the 95th percentile for the age, gender and height of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"     4",
"    </a>",
"    ]. The need for confirmation of the diagnosis with a persistently elevated BP was illustrated in a large cohort study of children cared for in community-based practices [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/15\">",
"     15",
"    </a>",
"    ]. Initial BP measurement was normal, prehypertensive, and hypertensive (defined &ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) in 82, 13, and 5 percent of children, who were of diverse race and ethnicity. At follow-up, subsequent hypertensive measurements were observed in only 4 percent of the 10,848 children who had initial hypertensive values. This resulted in an overall prevalence of 0.3 percent.",
"   </p>",
"   <p>",
"    The one exception is in the symptomatic child with stage 2 hypertension, evaluation and treatment should be initiated without further BP measurements.",
"   </p>",
"   <p>",
"    The diagnosis of HTN is dependent upon routine accurate measurements of BP throughout childhood using a standardized procedure and equipment. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Measurement of blood pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite the awareness of the increasing prevalence of HTN [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] and the routine measurement of BP, pediatric HTN is often unrecognized [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This was illustrated in analysis of electronic medical data obtained on 14,187 children from 3 to 18 years of age seen in a network of clinics affiliated with an academic medical center in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/18\">",
"     18",
"    </a>",
"    ]. Of the 507 patients who had HTN (3.6 percent of the total group), defined as three BP measurements greater than the 95th percentile, only 131 patients (26 percent of the hypertensive group) were noted to have a diagnosis of HTN or elevated blood pressure documented in the electronic medical record. Factors that increased the likelihood of a documented diagnosis of HTN included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      More than three readings of elevated blood pressure measurements",
"     </li>",
"     <li>",
"      Stage 2 HTN",
"     </li>",
"     <li>",
"      Increasing age",
"     </li>",
"     <li>",
"      Increased height for age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Frequency of monitoring BP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we follow the recommendations by the National High Blood Pressure Education Program Working Group (NPBPEP) and the American Heart Association Council on High Blood Pressure Research on routine BP measurements in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children less than three years old should have their BP measured if they have a history of neonatal complications requiring neonatal intensive care, congenital heart disease, recurrent urinary tract infection, hematuria, proteinuria, known renal or urologic disease, family history of congenital renal disease, solid organ or bone marrow transplantation, malignancy, treatment with drugs known to raise BP, other systemic illnesses associated with HTN, or evidence of increased intracranial pressure.",
"     </li>",
"     <li>",
"      All children greater than three years old should have their BP measured during routine office and emergency visits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine BP monitoring identifies children with HTN or prehypertension who are at risk for HTN as adults as discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Timing of follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of repeat blood pressure measurements is dependent upon the initial BP and the presence of symptoms associated with hypertension as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4,21\">",
"     4,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal BP &ndash; Recheck at next regularly schedule primary care visit.",
"     </li>",
"     <li>",
"      Prehypertension &ndash; Recheck in six months.",
"     </li>",
"     <li>",
"      Stage 1 HTN &ndash; Recheck within one to two weeks (or sooner if the patient is symptomatic). If BP remains elevated on two separate occasions, the patient should be evaluated for hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link\">",
"       \"Evaluation of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stage 2 HTN &ndash; If the patient is symptomatic, evaluation for HTN should proceed immediately. If the patient is not symptomatic, evaluation should be performed within the week. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link\">",
"       \"Evaluation of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tracking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracking refers to the pattern of repeated BP measurements over time. The clinical importance of tracking in children with annual BP over the age of three years is related to the ability to predict BP status later in childhood and adulthood. Children who are hypertensive are more likely to remain hypertensive throughout childhood and as adults, particularly in the presence of a family history of HTN, increased body weight, or increased left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link\">",
"     \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These principles were illustrated in a report from the Bogalusa Heart Study in which 1501 children (2 to 14 years of age) were examined four times during an eight-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/22\">",
"     22",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children in the upper quartile of BP on any single examination, the likelihood of remaining in the upper quartile at the end of the study ranged from 41 to 52 percent for systolic BP (SBP) and from 35 to 44 percent for diastolic BP (DBP).",
"     </li>",
"     <li>",
"      A family history of HTN independently predicted SBP at the last examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The BP during adolescence is predictive of BP in adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. This was best illustrated by the Muscatine longitudinal BP study in which BP, height, and weight were measured every other year between the ages of 7 and 18 years and again between the ages of 20 and 30 years in almost 2500 children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/1\">",
"     1",
"    </a>",
"    ]. Among children with any systolic or diastolic BP reading above the 90th percentile, 24 to 25 percent of adult readings were above the 90th percentile, and 32 percent of adult readings were above the 80th percentile. Among children with three or more readings, the risk of high BP as an adult was 6, 17, and 24 percent for children with no, one, or two or more BP levels above the 90th percentile, respectively.",
"   </p>",
"   <p>",
"    In the previously mentioned study that analyzed longitudinal data from the National Childhood Blood Pressure database, prehypertensive adolescents had an annual rate of progression to hypertension of 7 percent over a two year time period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, 31 percent of males and 26 percent of females who were hypertensive at the initial assessment remained hypertensive when re-evaluated two years later. These findings persisted in the subset of both prehypertensive and hypertensive patients who were followed for four years.",
"   </p>",
"   <p>",
"    Findings from a school-based blood pressure screening program also showed that adolescents with prehypertension were more likely to have subsequent BP measurements &ge; 95th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypertension (HTN) is dependent upon accurate blood pressure (BP) measurement.",
"   </p>",
"   <p>",
"    The variability of BP values due to procedural differences in the BP measurement was illustrated in a comparison of normal BP readings reported by 10 different investigators in which the BP values differed by as much as 20 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/27\">",
"     27",
"    </a>",
"    ]. Confounding factors included cuff size, technique used (ie, patient position and the choice of fourth or fifth Korotkoff sound to determine diastolic BP), the number of measurements made,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    type of instruments used. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Technique of BP measurement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cuff size",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of different cuff sizes are available, including adult, large adult, and thigh cuffs. The correct choice of cuff is important for accurate BP measurement. If too small a cuff is used, the pressure generated by inflating the cuff may not be fully transmitted to the brachial artery. In this setting, the pressure in the cuff may be considerably higher than the intraarterial pressure, leading to overestimation of the systolic pressure. On the other hand, too wide a cuff may produce lower readings than the actual intraarterial pressure.",
"   </p>",
"   <p>",
"    The cuff size should have a bladder width that is approximately 40 percent of the circumference of the upper arm, measured midway between the olecranon and the acromion (",
"    <a class=\"graphic graphic_figure graphicRef73414 \" href=\"UTD.htm?1/0/1025\">",
"     figure 1",
"    </a>",
"    ). The length of the cuff bladder should encircle 80 to 100 percent of the circumference of the upper arm midway between the olecranon and the acromion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4,20,28\">",
"     4,20,28",
"    </a>",
"    ]. The bladder width-to-length should be at least 1:2 (",
"    <a class=\"graphic graphic_table graphicRef58304 \" href=\"UTD.htm?36/49/37659\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The accuracy of BP readings with recommended bladder cuff widths compared with direct intraarterial measurements was evaluated in a review of 65 stable children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/29\">",
"     29",
"    </a>",
"    ]. Cuff widths using the 40 percent upper arm circumference criterion gave comparable readings to intraarterial measurements for systolic BP but overestimated diastolic BP by a mean of 7 mmHg. In comparison, cuffs with widths chosen by the previously recommended criteria (equal to two-thirds to three-fourths of the length of the upper arm) resulted in substantially and significantly lower values compared to intraarterial measurements for both systolic BP (15 to 17 mmHg) and diastolic BP (6 to 7 mmHg) because of the larger cuff.",
"   </p>",
"   <p>",
"    Another study reported that pediatric clinicians are likely to use a cuff with a bladder width that is greater than the 40 percent upper arm circumference recommended criterion, particularly in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62655769\">",
"    <span class=\"h2\">",
"     Auscultation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Technique of BP measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following steps are recommended to accurately measure BP by auscultation and compare values to normative data [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4,20,28,31\">",
"     4,20,28,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to BP measurement, stimulant drugs or food should be avoided.",
"     </li>",
"     <li>",
"      The BP should be measured after five minutes of rest in a quiet environment. The child should be seated with",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      back and feet in a supported position. In infants, BP is measured in a supine position.",
"     </li>",
"     <li>",
"      Because anxiety acutely raises both the heart rate and BP, the most reproducible readings are obtained when the pulse rate is both steady and within the normal range. Measurements made in noncooperative, agitated children are often misleading. Measuring BP when the heart rate is normal and steady can minimize the likelihood of obtaining falsely elevated readings.",
"     </li>",
"     <li>",
"      Because BP normative data are based upon BP measurement recorded by auscultation, the preferred method of BP measurement is auscultation. Although the mercury sphygmomanometer is the most accurate instrument, its availability is restricted because of the potential risk of mercury poisoning. Although there are small discrepancies between mercury and aneroid measurements of both systolic and diastolic BPs, the variations are not clinically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/32\">",
"       32",
"      </a>",
"      ]. Because of the high correlation between measurements of the two devices, aneroid sphygmomanometer can be used when a mercury device is not available. The aneroid manometers need to be calibrated on a semi-annual basis. &nbsp;The BP is measured by auscultation using a stethoscope placed over the brachial artery pulse in the cubital fossa (",
"      <a class=\"graphic graphic_figure graphicRef64977 \" href=\"UTD.htm?5/25/5535\">",
"       figure 2",
"      </a>",
"      ). The BP should be taken with the patient's right arm supported at the level of the heart. The right arm is preferred in repeated measures of BP for consistency and comparison with standard tables. In addition, the possibility of coarctation of the aorta would lead to falsely low BP readings in the left arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allowing the arm to hang below the heart will elevate BP levels by the added hydrostatic pressure induced by gravity (as much as 10 to 12 mmHg in adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/33\">",
"     33",
"    </a>",
"    ]. The sphygmomanometer should be visible but does not have to be at the level of the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cuff should be inflated to 20 to 30 mmHg above the anticipated systolic BP and then deflated slowly at a rate of 2 to 3 mmHg per heartbeat. The systolic BP is equal to the pressure at which the brachial pulse can first be heard by auscultation (Korotkoff phase I). As the cuff is deflated below the SBP, the pulse continues to be heard until there is abrupt muffling (Korotkoff phase IV) followed by disappearance of sound (Korotkoff phase V) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phase V is recommended for DBP determination in children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"     4",
"    </a>",
"    ] as well as adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/5\">",
"     5",
"    </a>",
"    ]. In some children, Korotkoff sounds can be heard to 0 mmHg. If this occurs, BP measurement should be repeated with less pressure on the head of the stethoscope. If phase V is still very low, phase IV (muffling) should be recorded as the DBP with the added documentation noting the use of the phase IV to determine DBP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of children less than three years of age, Korotkoff phase I and V provided the most reliable estimate of systolic and diastolic BP when compared to blood pressure measurements obtained through an indwelling arterial catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coarctation of the aorta is one of the more common causes of HTN in young children. Thus, the BP should be measured in both arms and legs on the first visit, particularly if the pulses in the legs are absent or weak. The BP in the leg is measured by auscultation over the popliteal fossa using the appropriate size cuff. If the SBP in the legs is lower than 10 mmHg than that measured in the arms, further studies for coarctation of the aorta should be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Number of measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BP should be taken at least twice on each visit, with the measurements separated by one to two minutes to allow the release of trapped blood. If the second value is more than 5 mmHg different from the first, continued measurements should be made until a stable value is attained. The recorded value on the patient's chart should be the average of the last two measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new diagnosis of HTN should not be made until the systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic BP measurement is &ge;95th percentile on at least three separate visits, separated by days or weeks apart [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4,20,37\">",
"     4,20,37",
"    </a>",
"    ]. Many patients (both adults and children) have substantial reductions in BP between the first and third visits to a new doctor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The magnitude of this effect in children was illustrated in the following two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study involving over 14,600 children, a subset of 4252 junior high school-aged children had repeat BP measurements after initial BP screening [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/38\">",
"       38",
"      </a>",
"      ]. The incidence of systolic or diastolic HTN fell from 4.2 percent of patients based upon the initial BP measurement to 1.1 percent after two additional examinations.",
"     </li>",
"     <li>",
"      In the second study, BP measurements were performed in 5207 Swiss children in the sixth grade taken at few-week intervals [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/41\">",
"       41",
"      </a>",
"      ]. The prevalence of HTN (&gt;95th percentile for age, height, and gender) was 11.4, 3.8, and 2.2 percent on the first, second, and third visits, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The fall in BP with serial measurements is primarily because of two factors: an accommodation effect resulting from reduced anxiety over time, and regression to the mean [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Oscillometric devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oscillometric devices are increasingly used in practice because of their ease of use and decrease in observer bias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/42\">",
"     42",
"    </a>",
"    ]. They are particularly helpful when auscultation is difficult as with infants and neonates, in the intensive care setting when frequent BP measurement is needed, or to screen initial BP in a busy clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Automated oscillometric devices measure mean arterial BP based upon pressure oscillations of the brachial artery wall as the cuff is deflated. Systolic and diastolic BP measurements are calculated based on the mean BP. Manufacturers of oscillometric devices use different algorithms for these calculations.",
"   </p>",
"   <p>",
"    Limitations of the oscillometric devices include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a wide range of BP values when different devices are compared, with 30 percent of SBP measurements varying by more than 10 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When compared with auscultated BP measurements, oscillometric systolic and DBP readings are generally 10 mmHg higher as illustrated by the following studies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. These studies support the Task Force recommendations that BP readings &gt;90th percentile obtained with an oscillometric device be confirmed by auscultation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One English study that used the Omron Hem 711 oscillometric device found there was no correlation between auscultated and oscillometric BP readings [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/46\">",
"       46",
"      </a>",
"      ]. In this study, the Omron measurements tended to overestimate systolic BP when the BP was high, and underestimate when the BP was low.",
"     </li>",
"     <li>",
"      In a multicenter study of children with chronic kidney disease, oscillometric systolic and diastolic BP measurements using SpaceLabs 90217 oscillometric devices were consistently higher than those obtained by auscultation (ie, median elevations of 9 and 6 mm and for systolic and diastolic BP, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/47\">",
"       47",
"      </a>",
"      ]. The overestimation of both systolic and diastolic BP lead to frequent misclassification of BP with false positive diagnosis of hypertension or uncontrolled hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oscillometric devices require maintenance and repeated calibration. When routine maintenance is not followed, the accuracy of BP measurements may be affected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these limitations, caution should be used when interpreting BP results with these devices [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our institution, we follow the guidelines for BP measurements as recommended by the National High Blood Pressure Education Program Working Group and the American Heart Association Council on High Blood Pressure Research [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An appropriate cuff size to the size of the child's upper arm is required for accurate measurement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cuff size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to directly compare BP values with normative data, BP measurement should be performed in the right arm after the patient has been resting comfortably for at least three minutes in a seated position in a quiet environment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Technique of BP measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An oscillometric device is generally used to screen initial BP measurement. However, if a BP measurement exceeds the 90th percentile by oscillometry, it is confirmed by an auscultatory measurement. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Oscillometric devices'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Technique of BP measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the initial evaluation for HTN, blood pressure measurements are obtained in both upper and lower extremities to detect the possible presence of coarctation as the cause of hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the initial reading is high, at least two more BP measurements are obtained and spaced one or two minutes apart.",
"     </li>",
"     <li>",
"      During auscultation, the first (initial tapping sound) and fifth (disappearance) Korotkoff sounds are used to identify systolic and diastolic BP values, respectively. The blood pressure cuff is inflated 20 to 30 mmHg above the suspected systolic BP and then deflated slowly at a rate of 2 to 3 mmHg per heartbeat. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Number of measurements'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Technique of BP measurement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     AMBULATORY BP MEASUREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure (BP) changes continually in response to physiologic and environmental stimuli. In adults, 24-hour ambulatory BP monitoring (ABPM) has had better reproducibility and better correlation with the risk of hypertensive cardiovascular complications and target organ damage than office BP measurements.",
"   </p>",
"   <p>",
"    Data are more limited in children, but also indicate an important role of ABPM in the evaluation of hypertension (HTN) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17113/abstract/48\">",
"     48",
"    </a>",
"    ]. In particular, ABPM provides multiple measurements during regular activities and is the only method that allows BP measurement during sleep, and therefore is felt to provide a more accurate description of the patient's BP than office BP measurements. It is especially useful (and the only available method) to identify white coat HTN in children who are anxious in the medical setting, as well as those with masked hypertension with normal BP in the clinic setting and elevated BP by ABPM. For these reasons, ABPM has been advocated for use in the initial evaluation of children who have elevated BP or at-risk for elevated BP.",
"   </p>",
"   <p>",
"    ABPM also can give useful information regarding the BP pattern in patients with chronic kidney disease, diabetes, autonomic dysfunction, or episodic HTN, and the BP response to therapeutic intervention. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25943?source=see_link\">",
"     \"Ambulatory blood pressure monitoring in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/37/30290?source=see_link\">",
"       \"Patient information: High blood pressure in children (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=see_link\">",
"       \"Patient information: High blood pressure in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=see_link\">",
"       \"Patient information: High blood pressure treatment in children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension (HTN) in childhood and adolescence contributes to premature atherosclerosis and the early development of cardiovascular disease (CVD). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hypertension in children and adolescents\", section on 'Rationale for intervention'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H6#H6\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children, normal and elevated blood pressure (BP) is based upon the normative distribution of BP in healthy children. BP percentiles have been developed and are adjusted for age, gender, and height.",
"     </li>",
"     <li>",
"      The National High Blood Pressure Education Program (NHBPEP) Working Group revised the definition of normal and elevated BP in children in 2004. In the United States, these definitions are universally used to classify childhood BP measurements. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Normal BP is defined as both systolic and diastolic BP &lt;90th percentile.",
"     </li>",
"     <li>",
"      Prehypertension is defined as systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;90th percentile but &lt;95th percentile",
"      <strong>",
"       or",
"      </strong>",
"      if BP exceeds",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg even if &lt;90th percentile.",
"     </li>",
"     <li>",
"      HTN is defined as either systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;95th percentile measured upon three or more occasions. The degree of HTN is further delineated into two stages. Stage 1 HTN is defined as systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP between the 95th percentile and 5 mmHg above the 99th percentile. Stage 2 HTN is systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99th percentile plus 5 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of chronic childhood HTN is made when the auscultated BP values on",
"      <strong>",
"       three",
"      </strong>",
"      repeated and separate visits are greater than the 95th percentile for the age, gender and height of the patient. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children older than three years of age, blood pressure measurements should be obtained at all routine and emergency visits. In children younger than three years of age, BP should be measured if they have a history of neonatal complications requiring neonatal intensive care, congenital heart disease, recurrent urinary tract infection, hematuria, proteinuria, known renal or urologic disease, family history of congenital renal disease, solid organ or bone marrow transplantation, malignancy, treatment with drugs known to raise BP, other systemic illnesses associated with HTN, or evidence of increased intracranial pressure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Frequency of monitoring BP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who are hypertensive are more likely to be hypertensive as adults, particularly in the presence of a family history of HTN, increased body weight, or increased left ventricular mass. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Tracking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HTN is dependent upon accurate measurements of BP throughout childhood using a standardized procedure and equipment. In our practice, the following approach is used:",
"     </li>",
"     <li>",
"      An appropriate size cuff is used, defined as a bladder width of 40 percent of the circumference of the upper arm and a bladder length that encircles 80 to 100 percent of the circumference of the upper arm. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cuff size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BP measurement is performed in the right arm after the patient has been resting comfortably for at least three minutes in a seated position in a quiet environment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Technique of BP measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An oscillometric device is often used to screen initial BP. However if the BP value exceeds the 90th percentile by oscillometry, it should be confirmed by an auscultatory measurement. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Oscillometric devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the initial evaluation for HTN, BP measurements are obtained in both upper and lower extremities. At each visit, at least two BP measurements are obtained and spaced one or two minutes apart. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Technique of BP measurement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Number of measurements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When performing an auscultatory BP measurement, the first (initial tapping sound) and fifth (disappearance) Korotkoff sounds are used to identify systolic and diastolic blood pressure values, respectively. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Technique of BP measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ABPM provides multiple measurements during regular activities (including sleep) and may give a more accurate description of the patient's BP, especially children who are anxious in the medical setting (ie, white coat HTN). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25943?source=see_link\">",
"       \"Ambulatory blood pressure monitoring in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/1\">",
"      Lauer RM, Clarke WR. Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics 1989; 84:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/2\">",
"      Sun SS, Grave GD, Siervogel RM, et al. Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. Pediatrics 2007; 119:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/3\">",
"      Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 1987; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/4\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/5\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/6\">",
"      Rosner B, Prineas RJ, Loggie JM, Daniels SR. Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr 1993; 123:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/7\">",
"      Falkner B, Gidding SS, Portman R, Rosner B. Blood pressure variability and classification of prehypertension and hypertension in adolescence. Pediatrics 2008; 122:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/8\">",
"      Chiolero A, Bovet P, Paradis G, Paccaud F. Has blood pressure increased in children in response to the obesity epidemic? Pediatrics 2007; 119:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/9\">",
"      Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 2007; 116:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/10\">",
"      Watkins D, McCarron P, Murray L, et al. Trends in blood pressure over 10 years in adolescents: analyses of cross sectional surveys in the Northern Ireland Young Hearts project. BMJ 2004; 329:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/11\">",
"      Rosner B, Cook N, Portman R, et al. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 2008; 167:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/12\">",
"      Menghetti E, Virdis R, Strambi M, et al. Blood pressure in childhood and adolescence: the Italian normal standards. Study Group on Hypertension' of the Italian Society of Pediatrics'. J Hypertens 1999; 17:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/13\">",
"      Blake KV, Gurrin LC, Evans SF, et al. Reference ranges for blood pressure in preschool Australians, obtained by oscillometry. J Paediatr Child Health 2000; 36:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/14\">",
"      Jackson LV, Thalange NK, Cole TJ. Blood pressure centiles for Great Britain. Arch Dis Child 2007; 92:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/15\">",
"      Lo JC, Sinaiko A, Chandra M, et al. Prehypertension and hypertension in community-based pediatric practice. Pediatrics 2013; 131:e415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/16\">",
"      Sorof JM, Lai D, Turner J, et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 2004; 113:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/17\">",
"      McNiece KL, Poffenbarger TS, Turner JL, et al. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr 2007; 150:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/18\">",
"      Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007; 298:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/19\">",
"      Brady TM, Solomon BS, Neu AM, et al. Patient-, provider-, and clinic-level predictors of unrecognized elevated blood pressure in children. Pediatrics 2010; 125:e1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/20\">",
"      Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/21\">",
"      Lande MB, Flynn JT. Treatment of hypertension in children and adolescents. Pediatr Nephrol 2009; 24:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/22\">",
"      Shear CL, Burke GL, Freedman DS, Berenson GS. Value of childhood blood pressure measurements and family history in predicting future blood pressure status: results from 8 years of follow-up in the Bogalusa Heart Study. Pediatrics 1986; 77:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/23\">",
"      Katz SH, Hediger ML, Schall JI, et al. Blood pressure, growth and maturation from childhood through adolescence. Mixed longitudinal analyses of the Philadelphia Blood Pressure Project. Hypertension 1980; 2:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/24\">",
"      Beckett LA, Rosner B, Roche AF, Guo S. Serial changes in blood pressure from adolescence into adulthood. Am J Epidemiol 1992; 135:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/25\">",
"      Falkner B, Kushner H, Onesti G, Angelakos ET. Cardiovascular characteristics in adolescents who develop essential hypertension. Hypertension 1981; 3:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/26\">",
"      Redwine KM, Acosta AA, Poffenbarger T, et al. Development of hypertension in adolescents with pre-hypertension. J Pediatr 2012; 160:98.",
"     </a>",
"    </li>",
"    <li>",
"     Park MK, Troxler RG. Systemic hypertension. In: Pediatric Cardiology for Practitioners, 4th ed, Park MK (Ed), Mosby, St. Louis 2002. p.408.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/28\">",
"      Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002; 106:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/29\">",
"      Clark JA, Lieh-Lai MW, Sarnaik A, Mattoo TK. Discrepancies between direct and indirect blood pressure measurements using various recommendations for arm cuff selection. Pediatrics 2002; 110:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/30\">",
"      Arafat M, Mattoo TK. Measurement of blood pressure in children: recommendations and perceptions on cuff selection. Pediatrics 1999; 104:e30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/31\">",
"      Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. American Society of Hypertension. Am J Hypertens 1992; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/32\">",
"      Shah AS, Dolan LM, D'Agostino RB Jr, et al. Comparison of mercury and aneroid blood pressure measurements in youth. Pediatrics 2012; 129:e1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/33\">",
"      Beevers G, Lip GY, O'Brien E. ABC of hypertension: Blood pressure measurement. Part II-conventional sphygmomanometry: technique of auscultatory blood pressure measurement. BMJ 2001; 322:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/34\">",
"      Sinaiko AR, Gomez-Marin O, Prineas RJ. Diastolic fourth and fifth phase blood pressure in 10-15-year-old children. The Children and Adolescent Blood Pressure Program. Am J Epidemiol 1990; 132:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/35\">",
"      Knecht KR, Seller JD, Alpert BS. Korotkoff sounds in neonates, infants, and toddlers. Am J Cardiol 2009; 103:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/36\">",
"      Bailey RH, Bauer JH. A review of common errors in the indirect measurement of blood pressure. Sphygmomanometry. Arch Intern Med 1993; 153:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/37\">",
"      Gillman MW, Cook NR. Blood pressure measurement in childhood epidemiological studies. Circulation 1995; 92:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/38\">",
"      Sinaiko AR, Gomez-Marin O, Prineas RJ. Prevalence of \"significant\" hypertension in junior high school-aged children: the Children and Adolescent Blood Pressure Program. J Pediatr 1989; 114:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/39\">",
"      Hartley RM, Velez R, Morris RW, et al. Confirming the diagnosis of mild hypertension. Br Med J (Clin Res Ed) 1983; 286:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/40\">",
"      Watson RD, Lumb R, Young MA, et al. Variation in cuff blood pressure in untreated outpatients with mild hypertension--implications for initiating antihypertensive treatment. J Hypertens 1987; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/41\">",
"      Chiolero A, Cachat F, Burnier M, et al. Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight. J Hypertens 2007; 25:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/42\">",
"      Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol 2005; 20:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/43\">",
"      Kaufmann MA, Pargger H, Drop LJ. Oscillometric blood pressure measurements by different devices are not interchangeable. Anesth Analg 1996; 82:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/44\">",
"      Park MK, Menard SW, Yuan C. Comparison of auscultatory and oscillometric blood pressures. Arch Pediatr Adolesc Med 2001; 155:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/45\">",
"      Podoll A, Grenier M, Croix B, Feig DI. Inaccuracy in pediatric outpatient blood pressure measurement. Pediatrics 2007; 119:e538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/46\">",
"      Midgley PC, Wardhaugh B, Macfarlane C, et al. Blood pressure in children aged 4-8 years: comparison of Omron HEM 711 and sphygmomanometer blood pressure measurements. Arch Dis Child 2009; 94:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/47\">",
"      Flynn JT, Pierce CB, Miller ER 3rd, et al. Reliability of resting blood pressure measurement and classification using an oscillometric device in children with chronic kidney disease. J Pediatr 2012; 160:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17113/abstract/48\">",
"      Lurbe E, Sorof JM, Daniels SR. Clinical and research aspects of ambulatory blood pressure monitoring in children. J Pediatr 2004; 144:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6087 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17113=[""].join("\n");
var outline_f16_45_17113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Frequency of monitoring BP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Timing of follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tracking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MEASUREMENT OF BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cuff size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62655769\">",
"      Auscultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Technique of BP measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Number of measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Oscillometric devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      AMBULATORY BP MEASUREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6087|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/0/1025\" title=\"figure 1\">",
"      Determining BP cuff size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/25/5535\" title=\"figure 2\">",
"      Blood pressure measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6087|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 1\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 2\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/49/37659\" title=\"table 3\">",
"      BP cuff sizes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25943?source=related_link\">",
"      Ambulatory blood pressure monitoring in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=related_link\">",
"      Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=related_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=related_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/37/30290?source=related_link\">",
"      Patient information: High blood pressure in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=related_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_45_17114="Acute pain management in adults with sickle cell disease";
var content_f16_45_17114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute pain management in adults with sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17114/contributors\">",
"     Michael R DeBaun, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17114/contributors\">",
"     Elliott P Vichinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17114/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17114/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17114/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/45/17114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/45/17114/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/45/17114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute, painful episodes are the most common cause for patients with sickle cell disease (SCD) to seek medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/1\">",
"     1",
"    </a>",
"    ]. While the annual incidence rate of pain episodes increases with age, rates in adults with SCD are underestimated because the majority of such episodes are managed at home [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No evidence-based guidelines exist for the treatment of SCD-associated acute pain episodes, either in the hospital or at home. However, reasonable strategies for patient care management can be employed, based on established principles of pain management and pharmacokinetics of opioids. These will be discussed here. Overviews of the management of pain are available elsewhere in UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and overall management of the individual with SCD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Acute painful episodes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of pain events in SCD differs depending upon the definition used for an acute pain event. The Cooperative Study of Sickle Cell Disease (CSSCD) defined a pain episode as pain related to SCD in the extremities, back, abdomen, chest or head lasting at least two hours and leading to a clinic visit or hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators from the CSSCD prospectively collected data on 3578 children and adults with SCD, documenting 12,290 pain episodes in 18,356 patient-years. The annual incidence rate of pain differed significantly based on SCD phenotype. Mean rates of pain episodes were 0.8 and 1.0 per year for patients with HbSS and",
"    <span class=\"nowrap\">",
"     HbS/beta(0)",
"    </span>",
"    thalassemia, respectively. For patients with HbSC or",
"    <span class=\"nowrap\">",
"     HbS/beta(+)",
"    </span>",
"    thalassemia, the mean rate was significantly lower (0.4",
"    <span class=\"nowrap\">",
"     episodes/year).",
"    </span>",
"    Risk factors for pain included older age, lower fetal hemoglobin level, and higher hemoglobin measurements. Adults with HbSS ages 25 to 29 years had a rate of 1.2 pain episodes per year compared with a rate of 0.4 per year for children who were less than four years of age.",
"   </p>",
"   <p>",
"    However, most adults with SCD who have pain episodes do not seek medical attention. This was shown in a prospective study in which 232 adults with SCD completed a daily pain diary for up to six months, which included maximum daily pain score and whether they developed an acute pain episode. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Home management of acute pain episodes was reported in 13 percent of the days. Pain episodes that required a physician contact and health care utilization (eg, office visit, ED visit, hospitalization) made up only 4 percent of total days.",
"     </li>",
"     <li>",
"      Approximately one-third of the patients had acute or chronic pain approximately 95 percent of the time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, many adults with SCD have pain on an almost daily basis, and the vast majority of acute pain episodes are managed at home. As a result, many adults with SCD present to the hospital or emergency department only when their pain exceeds what they can manage at home with oral opioids. Accordingly, management strategies describing when to start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    that depend upon the frequency of",
"    <strong>",
"     hospitalization",
"    </strong>",
"    for pain underestimate the need for such treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H558387868#H558387868\">",
"     \"Specific therapies for sickle cell disease\", section on 'Indications and clinical benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pain as a risk factor for morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with SCD are at an increased risk for acute chest syndrome (ACS) and death concomitant with a pain episode. Those who have an increased incidence rate of pain have a higher mortality rate when compared with those with lower rates. Based on data from the CSSCD, in which the circumstances of death were examined in 209 patients who were over 20 years of age when they died, the following were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-five deaths (22 percent) occurred during a pain episode. Of these events, 20 were complicated by an episode of ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACS episodes were temporally related to pain events that required hospitalization in 72 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Individuals over age 20 years with a higher incidence rate of pain were at an increased risk of premature death when compared with those with a lower rate of pain [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Triggers for pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most adults with SCD are aware of their triggers for vaso-occlusive pain episodes and are sensitive to avoiding them. Established precipitants of pain include extremely cold temperatures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], change in weather [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], over-exertion, dehydration, onset of menses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], direct or indirect exposure to tobacco smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/11\">",
"     11",
"    </a>",
"    ], and concomitant exacerbation of co-morbid conditions such as asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/12\">",
"     12",
"    </a>",
"    ] or sarcoidosis.",
"   </p>",
"   <p>",
"    Ecological studies have provided additional evidence that cold weather [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/13\">",
"     13",
"    </a>",
"    ], wind speed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and air pollution [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/16\">",
"     16",
"    </a>",
"    ] may also be associated with an increased rate of pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Acute painful episodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF ACUTE PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoocclusion with resulting tissue ischemia and inflammation is the basis for much of SCD-related pain. Acute episodes of vasoocclusive pain may also occur along with chronic pain due to the presence of such SCD-related complications as compression fractures, avascular necrosis, arthropathies, or leg ulcers, or may be due to coexisting conditions not related to SCD (eg, trauma or arthritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=see_link\">",
"     \"Vasoocclusion in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main locations for acute pain in SCD are upper back (63 percent), left arm (61 percent), and, in decreasing order of frequency, legs (38 percent), chest (26 percent), and lower back (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When adults with SCD present to the hospital for a pain episode, the pain was rated as a mean of 95 mm (out of 100 mm) on the Visual Analogue Scale on admission, and 48 mm upon hospital discharge (",
"    <a class=\"graphic graphic_form graphicRef50711 \" href=\"UTD.htm?30/49/31518\">",
"     form 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/19\">",
"     19",
"    </a>",
"    ]. When asked in a systematic fashion to describe the character of their pain, adults with SCD often used descriptors associated with nociceptive (secondary to tissue ischemia) and neuropathic (secondary to aberrant somatosensory input) pain.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For nociceptive pain, the major self-report descriptors included aching, throbbing, sharp, hurting, and pounding [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/18,20\">",
"       18,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Descriptors more consistent with neuropathic pain include shooting, stabbing, and penetrating [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/18,20\">",
"       18,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the observation that, during a pain episode, neuropathic pain symptoms have been described in adults with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ], the majority of symptoms are secondary to nociceptive pain and therapy should be directed to the treatment of nociceptive pain and not neuropathic pain. Formal studies are needed to provide evidence for the benefit of treatment of acute pain episodes that have features of neuropathic pain in SCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF PAIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stages of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four stages of a pain event have been described in adults with SCD: prodromal, initial, established, and resolving [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/23\">",
"     23",
"    </a>",
"    ]. Each stage is associated with subtle changes in clinical and laboratory findings that are overlapping and non-distinct.",
"    <strong>",
"     No combination of clinical and laboratory findings exists to determine if an individual is currently in pain",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef73221 \" href=\"UTD.htm?14/59/15294\">",
"     figure 1",
"    </a>",
"    ). As a result, the cornerstone of evaluating a pain episode in an individual with SCD is the trust between the individual and the treating healthcare provider(s).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Healthcare provider perception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many health care providers perceive that patients with SCD are addicted to opioids and exhibit drug-seeking behavior. These misconceptions about the frequency of opioid abuse in patients with SCD must be addressed on the clinical service in order to be able to deliver optimal care for pain episodes. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      86 percent of physicians in academic teaching hospital do not believe that self-report is the most reliable indicator of pain among individuals with SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a survey of ED physicians and hematologists, 50 percent and 23 percent, respectively, believed that patients with SCD were addicted to opioids [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a survey of the nurses who treat individuals with SCD, 63 percent believed that addiction was prevalent, and 30 percent were reluctant to provide high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      . Approximately 33 percent believed that a common barrier in the management of sickle cell pain was clinicians' reluctance to prescribe opioids (33 percent), and the belief that most individuals with SCD were drug addicts (32 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Opioid dependency in SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The percentage of adults with SCD who exhibit behavior consistent with substance abuse is similar to that seen in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/27\">",
"     27",
"    </a>",
"    ]. Large academic centers in Cincinnati, Philadelphia, and London have estimated the percent of adults with SCD abusing opioids to be in the range of zero to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. In comparison, in similar communities, the prevalence of substance abuse in the general population is 6 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/27,31\">",
"     27,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since there is a low prevalence of dependence in opioid-treated patients with SCD, the primary focus on treating an acute pain episode in SCD is relief of pain, not withholding medication because of the concern about drug dependency. Many physicians misinterpret opioid tolerance and physical dependence as addiction. These terms differ, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Addiction, in contrast to tolerance and physical dependence, is a psychological disorder.",
"     </li>",
"     <li>",
"      Tolerance refers to increasing dose requirements because of changes in drug metabolism.",
"     </li>",
"     <li>",
"      Physical dependence characterized by withdrawal symptoms is a normal occurrence after seven days of opioid exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When concerns about drug dependency are raised, they are best raised",
"    <strong>",
"     outside",
"    </strong>",
"    of the setting of an acute pain episode. In such situations, a multi-disciplinary approach is recommended, including a complete review of the opioid prescription history, discussion with the primary health care provider and psycho-social team (medical social worker, case worker, psychologist), and review of the hospitalization record for pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pain scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with SCD treated for pain should have an objective pain measurement to assess the impact of the treatment. Several measurements exist; however, no assessment tool has been evaluated in adults with SCD. Among children and adolescents with SCD, the Wong-Baker FACES (",
"    <a class=\"graphic graphic_figure graphicRef51021 \" href=\"UTD.htm?26/20/26944\">",
"     figure 2",
"    </a>",
"    ), the African-American Oucher scale, and the Visual Analog Scale (",
"    <a class=\"graphic graphic_form graphicRef50711 \" href=\"UTD.htm?30/49/31518\">",
"     form 1",
"    </a>",
"    ) have been examined [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common measurement for adults is the Visual Analog Scale (VAS), a continuous line, 100 mm in length, ranging from no pain to severe pain (",
"    <a class=\"graphic graphic_form graphicRef50711 \" href=\"UTD.htm?30/49/31518\">",
"     form 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/33\">",
"     33",
"    </a>",
"    ]. When treated in the ED, adults with SCD report that a change in the VAS of 13.5 mm is the minimum objective change that relates to a clinically significant subjective change in a vasoocclusive pain episode.",
"   </p>",
"   <p>",
"    Other guidelines have used a scale to assess response to therapy (0=none, 1=little, 2=moderate, 3=good, 4=complete) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sickle cell disease day hospitals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of day hospitals is to provide rapid evaluation and treatment of non-complicated pain episodes in individuals with SCD. Typically, patients are admitted to the facility under the care of medical and nursing staff familiar with the medical care of individuals with SCD. In these facilities the pain plan is typically based on the individual's own analgesic history. Studies have shown that day hospitals are superior to standard ED admissions for the key outcomes of decreased ED visits and hospital admissions. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study evaluating the utility of a day hospital versus prior standard care (ED utilization) in the same facility, ED visits decreased by 40 percent, inpatient hospital admissions decreased fivefold and length of stay decreased by 1.5 days for patients followed by the day hospital staff [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of a day hospital in the United Kingdom demonstrated a 43 percent decrease in hospital admissions and a 49 percent decrease in inpatient days when compared with a two-year period when there was no day hospital [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pain management at home",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of managing pain at home for adults with SCD are similar to WHO guidelines for the treatment of cancer-related pain, using a stepwise approach to match therapies with increasing pain severity (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"UTD.htm?0/45/724\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-opioid therapy is recommended for mild pain (",
"      <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      As pain severity increases, escalating strengths of opioids with and without adjuvant therapy is recommended (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When pain is severe, continuous opioid therapy is recommended to achieve pain control (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The caveat to these recommendations is that the population of adults with SCD has widely varying amounts of chronic pain and regular opioid use. On one extreme, 15 percent of adults have pain on fewer than 5 percent of days, while on the other end of the spectrum 30 percent of adults have chronic, daily pain. The subset of individuals with chronic pain will likely require opioids on a daily or regular basis for pain management and may have opioid tolerance.",
"   </p>",
"   <p>",
"    Approaches to the management of acute pain for this group of individuals are different than for individuals who are not taking daily opioids. Individuals who use opioids to manage pain on a regular basis will not achieve pain relief with non-opioid analgesics. In such cases, their pain plan should begin with a dose of opioids that gave relief during prior pain events.",
"   </p>",
"   <p>",
"    Given that individuals with SCD have most of their acute pain episodes at home, a standard care plan for treatment outside of the hospital is required. Pain treatment plans must be tailored to the individual. The treatment plan may vary considerably depending on factors such as medical comorbidities (eg, renal insufficiency), medication side effects, and presence of chronic pain with attendant daily opioid use and opioid tolerance. Plans will range from treatment with non-opioid analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , to prompt presentation to a day hospital for intravenous opioids.",
"   </p>",
"   <p>",
"    Given the compromise of renal blood flow in patients with SCD and the risk of acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], coupled with the evidence that adjuvant NSAID does not decrease pain in patients concomitantly treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/39\">",
"     39",
"    </a>",
"    ], NSAIDs should be utilized based on a case-by-case basis, should be avoided in those with renal involvement, and probably should not be used beyond five days.",
"   </p>",
"   <p>",
"    Many individuals with SCD who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    will not have pain relief because of a genetic polymorphism that decreases production of the active opioid. In a study of 73 children taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    who had failed codeine, 42 (58 percent) had reduced function alleles in CYP2D6 alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, before codeine is prescribed as part of the routine home pain therapy, both the individual and health care provider should be aware of a genetic predisposition to reduced functioning cytochrome P4502D6 alleles, and should have prior evidence that treatment with codeine provides relief for a mild pain episode.",
"   </p>",
"   <p>",
"    For individuals not taking opioids daily, stronger pain medication including controlled release opioids, such as controlled release (CR)-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    and CR-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , should be considered, combined with short-acting opioids for anticipated breakthrough pain if there is no relief with non-opioid therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    . Treatment with controlled release pain opioids can be continued for the duration of the pain event and then discontinued.",
"   </p>",
"   <p>",
"    Onset of action of controlled release opioids is important for individuals who do not require daily opioid therapy. In this setting, CR-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    is the preferred long-acting opioid for this group because time to onset of pain relief is commonly less than 40 minutes, and the duration of action is the longest in its class of drug, approximately 12 hours. Alternatively, CR-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    can be used, but the time of onset is commonly approximately two hours, and the action of duration is often between 8 and 12 hours.",
"   </p>",
"   <p>",
"    Individuals may be instructed to take a short-acting opioid, such as immediate-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , initially followed by CR-morphine two to four hours later to address CR-morphine&rsquo;s delayed onset of action. The optimal timing of this strategy has never been determined and will require individualized assessment, in some cases while the patient is in the hospital.",
"   </p>",
"   <p>",
"    If pain is not relieved according to the pre-specified pain plan, individuals should be instructed to either call their primary care provider or be evaluated in an ED familiar with the medical care of individuals with SCD, or be evaluated in a SCD day hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pain management in the emergency department",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of pain in individuals with SCD in the emergency department (ED) is based on the following cardinal principals as outlined by the American Pain Society (APS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/34,41,42\">",
"     34,41,42",
"    </a>",
"    ]. They include the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prompt treatment within 30 minutes with pain medication. By definition, Emergency Severity Index (ESI) triage of 2 for pain results in less than a 30 minute triage wait time.",
"     </li>",
"     <li>",
"      A reasonable starting dose of the opioid based on knowledge of the individual's previous pain episodes and the intensity of the current pain episode.",
"     </li>",
"     <li>",
"      Re-assessment shortly after the opioid administration is expected to take effect (eg, 20 minutes after administration for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , 5 to 10 minutes after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Placebo therapy should be",
"      <strong>",
"       avoided",
"      </strong>",
"      in the management of sickle cell disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The starting opioid dose for adults with SCD should, in part, be based on the dose that has previously and recently been established as an effective starting dose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , an intravenous dose of 0.1 to 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 10 mg) or for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      , an intravenous dose of 0.02 to 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 1.5 mg), with a reassessment in approximately 15 to 30 minutes after the completion of the infusion, is typically appropriate [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/41,43\">",
"       41,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Re-assessment of the initial pain relief is critical because an initial dose of 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , a dose at the lower limit of the recommended range, was not effective in decreasing pain intensity in about 50 percent of adults presenting to an ED for the relief of severe acute pain [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In situations where the previous starting dose was greater than the upper limit of the typical standard dose (eg, &gt;10 mg for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    or &gt;1.5 mg for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ), caution should be exercised. Of importance, an adjustment in the dose of opioid prior to the expected time of peak onset of pain relief (20 minutes for morphine or 10 minutes for hydromorphone) is not recommended. In the case of morphine and hydromorphone, increasing the dose within a 20 or 10 minute window following a prior injection, respectively, may lead to significant side effects, such as respiratory depression or somnolence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pain management in the hospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of pain in the hospital setting is typically achieved with scheduled opioid dosing or continuous infusion of opioids. The presence of a clinical pathway for the treatment of a pain episode in sickle cell disease may improve the quality of care of these patients, although results and outcomes have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. The success of these pathways is strongly dependent upon continuous education of the patients, nurses, and treating clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A management plan designed with the individual prior to admission is optimal. This will allow dosing to be individualized based on efficacy. Medication choices and dosing are determined by prior exposure, side effects, and tolerance. As examples, known renal dysfunction will affect the pain regimen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A creatine clearance in the range of 10 to 50",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      typically results in a dosage reduction to 75 percent of the standard dose.",
"     </li>",
"     <li>",
"      Severe renal failure (creatinine clearance &lt;10",
"      <span class=\"nowrap\">",
"       mL/minute)",
"      </span>",
"      requires a 50 percent reduction in the standard dose [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients should be assessed with objective pain tools and sedation scales. Oxygen saturation monitoring is helpful in managing patients during severe painful episodes. Orders should include temporary cessation of analgesia and physician notification if oxygen desaturation or bradypnea occurs.",
"   </p>",
"   <p>",
"    For an acute episode of pain that requires hospitalization, around-the-clock opioid therapy is required. A typical schedule is to give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    every two to three hours with a written order for breakthrough pain dosing, or administration of continuous morphine or hydromorphone using patient-controlled analgesia (PCA). (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An interval of intravenous opioids greater than three hours is of limited benefit for most patients, and is likely to result in poor relief of pain until the next dose of opioids is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Breakthrough pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge about breakthrough pain is critical in the management of SCD acute pain episodes. Breakthrough pain is defined as transitory pain that occurs intermittently while patients are receiving opioid therapy, that may last only a few minutes to an hour, and that is difficult to distinguish from the persistent pain.",
"   </p>",
"   <p>",
"    The hallmark of breakthrough pain is the swift increase in pain while the individual is being treated with continuous or around-the-clock opioid therapy. Accordingly, all patients being treated for continuous pain symptoms should have written orders for breakthrough pain medication in order to maintain them within the therapeutic \"window\" when the breakthrough pain occurs. This therapeutic window is bounded by side effects at too high a level (excessive sedation, respiratory depression) and no relief of pain at the lower level (",
"    <a class=\"graphic graphic_figure graphicRef67008 \" href=\"UTD.htm?26/60/27598\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two of the more common mistakes in treating breakthrough pain are either over-treating the episode by increasing the around-the-clock dose or a delay in the treatment of the breakthrough pain, such that it is given after the pain has subsided.",
"   </p>",
"   <p>",
"    Management of breakthrough pain with as needed pain orders (PRN) is often inadequate because, for some inpatient wards, nurses may have up to one hour to administer as needed (PRN) medication. The most reasonable solution is the use of patient-controlled analgesia (PCA) that allows the individual to administer an",
"    <strong>",
"     immediate",
"    </strong>",
"    dose of pain medication to relieve breakthrough pain without having to call the nurse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patient controlled analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the observation that an adult with SCD who is hospitalized for pain has an average length of stay of 9 to 11 days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/51\">",
"     51",
"    </a>",
"    ], a standardized plan of scheduled pain medication is preferred as opposed to as-needed (PRN) pain medication for two important reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no proven medical benefit for the use of PRN pain medication over scheduled pain mediation in an individual who is admitted for an acute episode of pain.",
"     </li>",
"     <li>",
"      PRN orders often lead to negative patient and nurse interaction, because approximately one-third of the nurses surveyed are reluctant to provide high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      PRN because of the belief that most individuals with SCD are drug addicts [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have evaluated the benefit of PCA delivery of opioids for an acute SCD pain episode.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized study of 45 patients with SCD who received either PCA or intermittent boluses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , those treated with PCA had similar pain control and used a similar amount of morphine over the course of the hospitalization compared with the group treated with bolus morphine. Side effects of opioids, including vital signs, respiratory rate, and level of alertness were equivalent between the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second randomized study of 25 adults with SCD compared PCA therapy with a continuous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      . The PCA group used less opioids during the hospitalization with similar pain scores [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A non-randomized study evaluated the use of PCA in a pediatric ED and included a patient survey. Ninety-two percent (48 of 50) of subjects who had received both PCA and intermittent bolus therapies in the past preferred PCA being initiated in the ED versus the standard bolus technique [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/54\">",
"       54",
"      </a>",
"      ]. Patients with a PCA received a demand dose within 35 minutes from the last bolus opioid dose in the ED versus 3.5 hours for patients who did not have a PCA. Subjects without PCA were dependent on the physician to order the opioid and the nurse to give the medication [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Initial treatment plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial pain regimen using continuous infusion of opioids and PCA may be estimated from the ED dosing when titrated to relieve pain and will differ between relatively opioid na&iuml;ve individuals and individuals taking opioids daily. Dosing history from prior hospitalizations can be very helpful when determining initial dosing, but the dose will still need to be evaluated on a case-by-case basis, particularly if the dose given in the ED is 20 percent of the typical initial dose for the patient.",
"   </p>",
"   <p>",
"    Three treatment strategies can be employed, depending upon whether the hospital allows continuous infusions of opioids (plans 1 and 2) or does not allow continuous infusions (plan 3).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preferred plan",
"      </strong>",
"      ��� Background continuous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      with PCA demand dosing is the preferred strategy and should only be administered in centers where experienced staff are able to provide the rigorous monitoring that is necessary to safely deliver this approach. We suggest the strategy offered by the American Pain Society expert panel on the treatment of pain, where the majority of the opioid dose is through the continuous intravenous route and one-sixth of the opioid hourly infusion is provided through PCA demand dosing every 20 minutes for morphine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      . The PCA dose is intended to substitute for the PRN dose that is commonly given for breakthrough pain and is not intended to replace the infusion of continuous morphine.",
"     </li>",
"     <li>",
"      Another strategy that has been endorsed is the use of continuous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      that is not intended to relieve the pain completely, but requires that the pain be relieved with the use of intermittent PCA. This strategy requires the patient to push the PCA demand button to relieve pain around the clock, including throughout the night, in order to stay within the therapeutic window. This strategy limits the number of hours of continuous sleep through the night because the patient must regularly hit the demand dose PCA to relieve his or her pain.",
"     </li>",
"     <li>",
"      <strong>",
"       No continuous infusion available",
"      </strong>",
"      ��� In the event that only a PCA demand dose is given to relieve pain, the patient is not expected to consistently be within the therapeutic window to relieve pain unless he or she hits the button around the clock, in intervals of approximately every two to three hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No definitive randomized trial has compared these three different strategies of using PCA with and without continuous infusion. Based on pharmacological principles, we prefer the strategy of titrating the opioid dose at the bedside that will place the individual into",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    therapeutic window for relieving pain with continuous infusion of an opioid and then providing a PCA dose (one-sixth of the continuous infusion dose) every 20 minutes for breakthrough pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18725412\">",
"    <span class=\"h3\">",
"     Dose adjustments",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the event that the patient has hit the PCA demand button more than three times an hour for several consecutive hours, we then consider increasing both the continuous and breakthrough pain dose. The new continuous infusion dose is started at the same level of the previous total amount of opioid received (continuous and PCA demand dose) in the previous hours, provided that the patient has not had any untoward side effects. Although the dose may be consider high, the patient has demonstrated his or her ability to handle this dose because of the ongoing pain and the absence of respiratory depression or somnolence.",
"   </p>",
"   <p>",
"    The new dose of the PCA should remain at one-sixth of the continuous infusion dose, allowing for housestaff, attendings, nursing staff, and pharmacists to double- and triple-check the amount of opioid provided during the continuous and PCA breakthrough dosing. This strategy will only work in the event that the medical and nursing staff work as a team to ensure that the patient remains comfortable, without being sedated, somnolent, or in respiratory depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824608\">",
"    <span class=\"h3\">",
"     Renal and hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with renal insufficiency are at higher risk for somnolence and respiratory depression associated with opioids due to accumulation of parent drug",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/55\">",
"     55",
"    </a>",
"    ]. Of the IV drugs commonly used in SCD management,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    has the highest risk for adverse effects in patients with renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/56\">",
"     56",
"    </a>",
"    ]. Although there is no difference in morphine levels between individuals with and without renal dysfunction, metabolites accumulate in the setting of renal dysfunction, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High levels of the metabolite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      -6-glucuronide occur in renal dysfunction and cause sedation and respiratory depression [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       Hydromorphone",
"      </a>",
"      is a safer alternative to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      in patients with renal dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]; however, the hydromorphone metabolite, hydromorphone-3-glucoronide, accumulates in renal dysfunction and has been associated with agitation, confusion and hallucinations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       Fentanyl",
"      </a>",
"      is principally metabolized in the liver to the inactive metabolite norfentanyl. Limited data suggest that fentanyl may be used safely in patients with renal dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, for patients with SCD and renal dysfunction, our practice is to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    PCA.",
"   </p>",
"   <p>",
"    Opioids are converted to active or inactive metabolites in the liver. In the setting of significant hepatic dysfunction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    may not be converted to metabolites, resulting in the accumulation of the parent drug and toxicity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    does not appear to be affected by hepatic dysfunction and is also the drug of choice in patients with liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824616\">",
"    <span class=\"h3\">",
"     Low-dose infusion of naloxone for management of opioid side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    is a &micro;-receptor antagonist that may provide relief from the nausea and pruritus associated with opioid use",
"    <strong>",
"     without",
"    </strong>",
"    affecting analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. Typically, low-dose infusional naloxone (0.25",
"    <span class=\"nowrap\">",
"     mcg/kg/hr)",
"    </span>",
"    is administered in conjunction with IV patient-controlled analgesia. Low-dose infusional naloxone should only be used by experienced practitioners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Weaning of opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence-based strategies to wean opioids have not been developed for patients with SCD; however, adherence to a few common-sense principles can provide the basis for a successful transition from the inpatient to outpatient setting with adequate pain control. These guidelines include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No weaning of opioids in the first 24 hours of a hospital admission unless there are signs of respiratory depression, increased lethargy, or other side effects associated with excessive amounts of opioids.",
"     </li>",
"     <li>",
"      Wean patients during the day when appropriate assessment of pain can be performed",
"     </li>",
"     <li>",
"      Wean off opioids incrementally, about 10 to 20 percent of the opioid dose at a time.",
"     </li>",
"     <li>",
"      Opioids should be weaned by decreasing the dose, rather than by increasing the interval between doses.",
"     </li>",
"     <li>",
"      Conversion to oral pain medication should occur when the intravenous dose is roughly equivalent to home doses of oral medications (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     When to discharge to home",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, patients can be discharged from the hospital when pain is adequately controlled on oral analgesics. We ensure that patients have prescriptions filled for pain medicines at the time of discharge and, when appropriate, instructions for weaning.",
"   </p>",
"   <p>",
"    All patients need a follow up visit in the outpatient clinic within two weeks of discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heating pads are a local measure that many patients with SCD find beneficial for pain control, although no formal studies have assessed their added value. Additional agents are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nonsteroidal anti-inflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not have a contraindication, nonsteroidal antiinflammatory drugs (NSAIDs) have been generally recommended for the at-home treatment of acute pain in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/70\">",
"     70",
"    </a>",
"    ]. Many small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uncontrolled studies were conducted to evaluate the benefit of NSAIDS for an acute SCD pain episode showing inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/71-75\">",
"     71-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of NSAIDs for inpatient management should be evaluated on a case-by-case basis because no evidence exists that this adjuvant therapy is beneficial in the inpatient setting.",
"   </p>",
"   <p>",
"    As an example, in the strongest randomized, placebo-controlled phase III clinical trial performed to date,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    , a non-selective cyclooxygenase inhibitor, at an oral dose of 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for five days, was evaluated as adjuvant therapy for a vasoocclusive pain episode requiring hospitalization. The primary endpoint was duration of the pain event and the secondary end points were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    consumption, pain relief, and treatment failure. No significant difference existed in the primary and secondary outcome measures between the ketoprofen and placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/39\">",
"     39",
"    </a>",
"    ]. These data suggest that ketoprofen in combination with an opioid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    does not hasten recovery to baseline in patients with vasoocclusive pain episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only randomized trial using intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    was conducted in children with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/76\">",
"     76",
"    </a>",
"    ]. In a double-blind, placebo-controlled trial, children with SCD who were admitted to the hospital for pain were randomly assigned to receive methylprednisolone or placebo. The participants who received methylprednisolone had a significant (approximately 50 percent) reduction in the length of hospitalization for pain when compared with the placebo group (31 versus 62.5 hrs, respectively).",
"   </p>",
"   <p>",
"    Despite this immediate benefit, approximately 25 percent of the patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    were re-admitted within a week of discharge, greatly attenuating the benefit of treatment with methylprednisolone for inpatient management of vasoocclusive pain. Based on these data, the use of corticosteroids solely for treating pain is not recommended unless in a clinical trial setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Volume status",
"    </span>",
"    &nbsp;&mdash;&nbsp;During painful episodes, individuals with SCD are frequently hypovolemic. Hyposthenuria, poor oral intake prior to and perhaps during the pain episode, and insensible losses may contribute to a negative fluid balance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/77\">",
"     77",
"    </a>",
"    ]. Further, this negative fluid balance may worsen as the episode progresses, resulting in loss of body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/77\">",
"     77",
"    </a>",
"    ]. Accordingly, when an individual with SCD is hospitalized for a pain episode, fluid intake and outtake must be carefully monitored, along with daily weights.",
"   </p>",
"   <p>",
"    For treatment of hypovolemia, we generally employ an initial intravenous bolus of 0.5 to 1 L of normal saline. Thereafter, we employ a maintenance rate of combined intravenous and oral fluid that contains at least",
"    <span class=\"nowrap\">",
"     1/4",
"    </span>",
"    normal saline (roughly 2",
"    <span class=\"nowrap\">",
"     L/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day), targeted to a net even or slightly positive daily fluid balance and a roughly stable body weight.",
"   </p>",
"   <p>",
"    Patients should be encouraged to drink fluids; it is important to place the fluids directly in front of the patient because individuals in severe pain will be largely confined to the bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14183184\">",
"    <span class=\"h2\">",
"     Inhaled nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its many beneficial effects on blood vasculature, inhaled nitric oxide (NO) was employed in two randomized, single-center, placebo-controlled trials in a total of 38 subjects with sickle cell disease-associated painful episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Initial results indicated some beneficial effects of inhaled NO on reducing pain scores and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    use.",
"   </p>",
"   <p>",
"    A larger, prospective, multicenter, randomized, double-blind, placebo-controlled study reported on the results of inhaled NO in 150 patients presenting with vaso-occlusive pain crisis at 11 centers between October 5, 2004 and December 22, 2008. Treatment included sustained NO (or placebo) delivered for eight hours by face mask, followed by a nasal cannula pulse system for up to 72 hours, mixed with sufficient oxygen to achieve a constant fraction of inspired oxygen of 24 percent. Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the primary endpoint, there was no significant difference in the median time to resolution of the painful crisis between the NO (73 hours; 95% CI 46-91) and placebo groups (65.5 hours; 95% CI 48-84).",
"     </li>",
"     <li>",
"      Similarly, for the secondary outcome measures (length of hospitalization, visual analog pain scale scores, cumulative opioid use, rate of acute chest syndrome) there were no significant differences between the NO and placebo groups.",
"     </li>",
"     <li>",
"      Increases in venous methemoglobin concentration confirmed adherence and randomization, but did not exceed 5 percent in any participant. Inhaled NO was well tolerated, with no increase in serious adverse events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were broad and overlapping confidence intervals for the primary outcome, leaving open the possibility that a small treatment effect may have been missed in this study. However, if such a treatment effect exists, it is likely to be less than a 25 percent reduction in crisis duration.",
"   </p>",
"   <p>",
"    Clinical trials that have focused on increasing NO availability either directly, as is the case with the large multi-center inhaled NO trial described above, or indirectly by administering arginine, an amino acid postulated to increase plasma levels of NO, have not shown any demonstrable clinical benefit. Until more definitive trials are done, inhaled NO should",
"    <strong>",
"     not",
"    </strong>",
"    be used in a clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT OF COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Prevention and management of constipation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Respiratory complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective, randomized trial of children and young adults with SCD evaluated incentive spirometry for the prevention of respiratory complications. Twenty-nine patients were randomly assigned to receive 10 maximal inspirations using an incentive spirometer every two hours while awake versus no incentive spirometry during pain episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/81\">",
"     81",
"    </a>",
"    ]. Pulmonary complications were significantly reduced in those receiving incentive spirometry (5 versus 42 percent in the control group).",
"   </p>",
"   <p>",
"    A reasonable plan for an individual receiving opioid in the hospital includes the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H14#H14\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Respiratory depression'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When patients are receiving intravenous opioids, it is critical to monitor pulse oximetry.",
"     </li>",
"     <li>",
"      Incentive spirometry should be performed every two hours while the patient is awake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Venous thromboembolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The determination of which patients with SCD might require prophylaxis against venous thromboembolism (VTE) during their hospitalization is discussed separately. In general, VTE prophylaxis is considered reasonable for medical patients older than age 40 who have limited mobility for &ge;3 days, and have at least one thrombotic risk factor. All patients admitted to intensive care units are considered high risk for VTE and will require some form of thromboprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Risk factors for VTE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H37#H37\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Assignment of risk group'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When prophylaxis is required, we generally employ either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    5000 units subcutaneous three times daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg subcutaneously once daily for VTE prophylaxis while the patient is in the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histamine release, resulting in pruritus, is a common problem with all narcotic analgesics, and often requires anti-histamine therapy. We have found continuous infusion of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    (0.25",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per hour) very helpful in decreasing pruritus without requiring opioid adjustment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/45/17114/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H16#H16\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Pruritus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    are compatible in the same intravenous line and can be infused simultaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Meperidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     Meperidine",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     recommended",
"    </strong>",
"    for the treatment of painful episodes of SCD, because multiple doses are associated with accumulation of normeperidine and central nervous system toxicity, including but not limited to mild twitching, multifocal clonus, and seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Acute pain plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every adult with sickle cell disease (SCD) should have an established pain plan tailored to",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    individual needs. This plan should instruct the individual how to appropriately manage mild, moderate, and severe pain, with a pre-defined threshold for the use of opioids and when to contact health care providers. Optimally, an individualized pain plan has been established in the ED with the hematology team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Home management of pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For individuals with SCD who do not take pain medicine on a regular basis, we follow a step-wise approach for treating pain starting with either non-opioids (NSAIDs) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      for mild pain and escalating to stronger opioids for moderate to severe pain. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pain management at home'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require long-acting opioids on a regular basis, additional short-acting breakthrough medication (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      , dilaudid) should be initiated to treat the pain event.",
"     </li>",
"     <li>",
"      If adequate relief is not achieved with pain management at home using oral analgesics, the individual should be evaluated by a healthcare provider (eg, private clinician, clinic, sickle cell disease day hospital, or emergency department (ED)).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Pain management in the ED",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients presenting to the ED with severe pain, we suggest the following (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Pain management in the emergency department'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      (0.1 to 0.15",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      (0.015 to 0.02",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      with reassessment of pain in 15 to 30 minutes after the dose is administered.",
"     </li>",
"     <li>",
"      Patients with severe pain may require repeated doses of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      0.02 to 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 20 to 30 minutes to achieve pain relief.",
"     </li>",
"     <li>",
"      If adequate pain relief is achieved with a single dose, consider discharge to home on long-acting opioids (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      CR) with a prescription for medication for breakthrough pain.",
"     </li>",
"     <li>",
"      If the individual does not typically require long-acting opioids at home, we recommend discontinuing the long-acting opioids when the pain event subsides.",
"     </li>",
"     <li>",
"      Hospitalization should be considered for around-the-clock parenteral analgesics if more than two doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      are required to control the pain episode.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Inpatient management of pain episodes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IV opioids with a PCA should be considered an initial option. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patient controlled analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial inpatient care in patients who are not taking opioids routinely, we suggest the use of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine sulfate",
"      </a>",
"      at 0.1 to 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two hours or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      , 0.015 to 0.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every three hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Reassessment is required 15 to 30 minutes after each dose is administered. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pain management in the hospital'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When pain relief is not achieved with intermittent dosing of opioids, we suggest the use of a continuous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      , preferably with a patient controlled analgesia (PCA) program that allows additional demand dosing. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patient controlled analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are relatively opioid na&iuml;ve should be managed differently than patients on a chronic opioid regimen.",
"     </li>",
"     <li>",
"      In the setting of significant renal or hepatic dysfunction,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      is the IV opioid of choice.",
"     </li>",
"     <li>",
"      Use of benzodiazepines for insomnia should be avoided as they may predispose the patient to respiratory depression.",
"     </li>",
"     <li>",
"      Use of phenothiazines for nausea should be avoided as this may potentiate sedative effects. In the event that nausea is associated with opioid administration, we recommend odansetron administration.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/1\">",
"      Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/2\">",
"      Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008; 148:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/3\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/4\">",
"      Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/5\">",
"      Redwood AM, Williams EM, Desal P, Serjeant GR. Climate and painful crisis of sickle-cell disease in Jamaica. Br Med J 1976; 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/6\">",
"      Resar LM, Oski FA. Cold water exposure and vaso-occlusive crises in sickle cell anemia. J Pediatr 1991; 118:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/7\">",
"      Ibrahim AS. Relationship between meteorological changes and occurrence of painful sickle cell crises in Kuwait. Trans R Soc Trop Med Hyg 1980; 74:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/8\">",
"      Amjad H, Bannerman RM, Judisch JM. Letter: Sickling pain and season. Br Med J 1974; 2:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/9\">",
"      Westerman MP, Bailey K, Freels S, et al. Assessment of painful episode frequency in sickle-cell disease. Am J Hematol 1997; 54:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/10\">",
"      Yoong WC, Tuck SM. Menstrual pattern in women with sickle cell anaemia and its association with sickling crises. J Obstet Gynaecol 2002; 22:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/11\">",
"      Cohen RT, DeBaun MR, Blinder MA, et al. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. Blood 2010; 115:3852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/12\">",
"      Glassberg J, Spivey JF, Strunk R, et al. Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. J Pediatr Hematol Oncol 2006; 28:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/13\">",
"      Smith WR, Bauserman RL, Ballas SK, et al. Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain 2009; 146:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/14\">",
"      Nolan VG, Zhang Y, Lash T, et al. Association between wind speed and the occurrence of sickle cell acute painful episodes: results of a case-crossover study. Br J Haematol 2008; 143:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/15\">",
"      Jones S, Duncan ER, Thomas N, et al. Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haematol 2005; 131:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/16\">",
"      Yallop D, Duncan ER, Norris E, et al. The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. Br J Haematol 2007; 136:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/17\">",
"      Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am 2005; 19:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/18\">",
"      Wilkie DJ, Molokie R, Boyd-Seal D, et al. Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease. J Natl Med Assoc 2010; 102:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/19\">",
"      Ballas SK, Reyes PE. Peripheral neuropathy in adults with sickle cell disease. Am J Pain Med 1997; 71:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/20\">",
"      Ballas SK, Delengowski A. Pain measurement in hospitalized adults with sickle cell painful episodes. Ann Clin Lab Sci 1993; 23:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/21\">",
"      Kirson LE, Tomaro AJ. Mental nerve paresthesia secondary to sickle-cell crisis. Oral Surg Oral Med Oral Pathol 1979; 48:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/22\">",
"      Konotey-Ahulu FI. Mental-nerve neuropathy: a complication of sickle-cell crisis. Lancet 1972; 2:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/23\">",
"      Ballas SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin 1995; 19:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/24\">",
"      Labb&eacute; E, Herbert D, Haynes J. Physicians' attitude and practices in sickle cell disease pain management. J Palliat Care 2005; 21:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/25\">",
"      Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage 1997; 14:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/26\">",
"      Pack-Mabien A, Labbe E, Herbert D, Haynes J Jr. Nurses' attitudes and practices in sickle cell pain management. Appl Nurs Res 2001; 14:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/27\">",
"      Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood 2008; 111:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/28\">",
"      Payne R. Pain management in sickle cell disease. Rationale and techniques. Ann N Y Acad Sci 1989; 565:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/29\">",
"      Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med 1992; 116:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/30\">",
"      Okpala I, Tawil A. Management of pain in sickle-cell disease. J R Soc Med 2002; 95:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/31\">",
"      Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/32\">",
"      Luffy R, Grove SK. Examining the validity, reliability, and preference of three pediatric pain measurement tools in African-American children. Pediatr Nurs 2003; 29:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/33\">",
"      Ho K, Spence J, Murphy MF. Review of pain-measurement tools. Ann Emerg Med 1996; 27:427.",
"     </a>",
"    </li>",
"    <li>",
"     American Pain Society. Guideline for the management of acute and chronic pain in sickle cell disease. 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/35\">",
"      Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000; 95:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/36\">",
"      Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol 2004; 126:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/37\">",
"      Schaller S, Kaplan BS. Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Pediatr Emerg Care 1998; 14:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/38\">",
"      Simckes AM, Chen SS, Osorio AV, et al. Ketorolac-induced irreversible renal failure in sickle cell disease: a case report. Pediatr Nephrol 1999; 13:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/39\">",
"      Bartolucci P, El Murr T, Roudot-Thoraval F, et al. A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood 2009; 114:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/40\">",
"      Brousseau DC, McCarver DG, Drendel AL, et al. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 2007; 150:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/41\">",
"      Benjamin LD, Dampier CD, Jacox AK. Guideline for the management of acute and chronic pain in sickle-cell disease. J Pain 1999; :12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/42\">",
"      Tanabe P, Hafner JW, Martinovich Z, Artz N. Adult emergency department patients with sickle cell pain crisis: results from a quality improvement learning collaborative model to improve analgesic management. Acad Emerg Med 2012; 19:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/43\">",
"      National Institutes of Health. The Management of Sickle Cell Disease. National Heart, Lung, Blood Institute 2002; :4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/44\">",
"      Bijur PE, Kenny MK, Gallagher EJ. Intravenous morphine at 0.1 mg/kg is not effective for controlling severe acute pain in the majority of patients. Ann Emerg Med 2005; 46:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/45\">",
"      Co JP, Johnson KB, Duggan AK, et al. Does a clinical pathway improve the quality of care for sickle cell anemia? Jt Comm J Qual Saf 2003; 29:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/46\">",
"      Jayaram A, Nagel RW, Jasty R. Impact of clinical pathway on quality of care in sickle cell patients. J Pediatr Hematol Oncol 2010; 32:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/47\">",
"      Morrissey LK, Shea JO, Kalish LA, et al. Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer 2009; 52:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/48\">",
"      Frei-Jones MJ, Field JJ, DeBaun MR. Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. Pediatr Blood Cancer 2009; 53:401.",
"     </a>",
"    </li>",
"    <li>",
"     Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook, 14th ed, Lexicomp, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/50\">",
"      Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care 1998; 15:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/51\">",
"      Ballas SK. Current issues in sickle cell pain and its management. Hematology Am Soc Hematol Educ Program 2007; :97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/52\">",
"      Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain. Comparison in patients in the emergency department. Arch Intern Med 1991; 151:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/53\">",
"      van Beers EJ, van Tuijn CF, Nieuwkerk PT, et al. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol 2007; 82:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/54\">",
"      Melzer-Lange MD, Walsh-Kelly CM, Lea G, et al. Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatr Emerg Care 2004; 20:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/55\">",
"      Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/56\">",
"      Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 1986; 292:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/57\">",
"      Sear JW, Hand CW, Moore RA, McQuay HJ. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Br J Anaesth 1989; 62:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/58\">",
"      Grass JA. Patient-controlled analgesia. Anesth Analg 2005; 101:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/59\">",
"      Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001; 15:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/60\">",
"      Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995; 10:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/61\">",
"      Fainsinger R, Schoeller T, Boiskin M, Bruera E. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993; 9:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/62\">",
"      Mercadante S, Caligara M, Sapio M, et al. Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage 1997; 13:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/63\">",
"      Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 2005; 33:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/64\">",
"      Murphy JD, Gelfand HJ, Bicket MC, et al. Analgesic efficacy of intravenous naloxone for the treatment of postoperative pruritus: a meta-analysis. J Opioid Manag 2011; 7:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/65\">",
"      Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 2004; 107:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/66\">",
"      Sartain JB, Barry JJ, Richardson CA, Branagan HC. Effect of combining naloxone and morphine for intravenous patient-controlled analgesia. Anesthesiology 2003; 99:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/67\">",
"      Gan TJ, Ginsberg B, Glass PS, et al. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997; 87:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/68\">",
"      Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 2005; 100:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/69\">",
"      Frei-Jones MJ, Field JJ, DeBaun MR. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr Blood Cancer 2009; 52:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/70\">",
"      Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology Am Soc Hematol Educ Program 2005; :58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/71\">",
"      Goodman E. Use of ketorolac in sickle-cell disease and vaso-occlusive crisis. Lancet 1991; 338:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/72\">",
"      Wright SW, Norris RL, Mitchell TR. Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. Ann Emerg Med 1992; 21:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/73\">",
"      Perlin E, Finke H, Castro O, et al. Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis. Am J Hematol 1994; 46:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/74\">",
"      Hardwick WE Jr, Givens TG, Monroe KW, et al. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care 1999; 15:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/75\">",
"      Beiter JL Jr, Simon HK, Chambliss CR, et al. Intravenous ketorolac in the emergency department management of sickle cell pain and predictors of its effectiveness. Arch Pediatr Adolesc Med 2001; 155:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/76\">",
"      Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/77\">",
"      HATCH FE, DIGGS LW. FLUID BALANCE IN SICKLE-CELL DISEASE. Arch Intern Med 1965; 116:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/78\">",
"      Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003; 289:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/79\">",
"      Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol 2010; 85:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/80\">",
"      Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011; 305:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/81\">",
"      Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/45/17114/abstract/82\">",
"      Kjellberg F, Tram&egrave;r MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001; 18:346.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7144 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17114=[""].join("\n");
var outline_f16_45_17114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pain as a risk factor for morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Triggers for pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS OF ACUTE PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ASSESSMENT OF PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stages of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Healthcare provider perception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Opioid dependency in SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pain scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sickle cell disease day hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pain management at home",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pain management in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pain management in the hospital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Breakthrough pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patient controlled analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Initial treatment plan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18725412\">",
"      - Dose adjustments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H824608\">",
"      - Renal and hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H824616\">",
"      - Low-dose infusion of naloxone for management of opioid side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Weaning of opioids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - When to discharge to home",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ADJUVANT THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nonsteroidal anti-inflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Volume status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14183184\">",
"      Inhaled nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PREVENTION AND TREATMENT OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Respiratory complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Meperidine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Acute pain plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Home management of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Pain management in the ED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Inpatient management of pain episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7144\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7144|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/59/15294\" title=\"figure 1\">",
"      Pain stages SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/20/26944\" title=\"figure 2\">",
"      Faces pain scale children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/45/724\" title=\"figure 3\">",
"      WHO analgesic ladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/60/27598\" title=\"figure 4\">",
"      Medication shortcomings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7144|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?30/49/31518\" title=\"form 1\">",
"      Monthly pain scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7144|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 1\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11760\" title=\"table 2\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_45_17115="Desquamative interstitial pneum";
var content_f16_45_17115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of desquamative interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Idiopathic DIP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        DIP-like reaction (often associated with other specific histologic findings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Respiratory bronchiolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Connective tissue diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eosinophilic granuloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asbestosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hard-metal pneumoconiosis (cobalt)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gaucher's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neimann-Pick disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hermansky-Pudlak syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nitrofurantoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Amiodarone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17115=[""].join("\n");
var outline_f16_45_17115=null;
var title_f16_45_17116="Early TPN extremely premature infants";
var content_f16_45_17116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Early total parenteral solution (TPN) for extremely premature infants*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Component",
"       </td>",
"       <td class=\"subtitle1\">",
"        Quantity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approximate intake, unit/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amino acids",
"       </td>",
"       <td>",
"        3.5 g/100 mL",
"       </td>",
"       <td>",
"        3.5&nbsp;g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        5 to 10 g/100 mL",
"       </td>",
"       <td>",
"        5 to 10 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium gluconate",
"       </td>",
"       <td>",
"        650 mg/100 mL",
"       </td>",
"       <td>",
"        650 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multivitamin-Pediatric",
"       </td>",
"       <td>",
"        2 mL/kg/day",
"       </td>",
"       <td>",
"        2 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc",
"       </td>",
"       <td>",
"        400 micrograms/kg/day",
"       </td>",
"       <td>",
"        400 micrograms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selenium",
"       </td>",
"       <td>",
"        2 micrograms/kg/day",
"       </td>",
"       <td>",
"        2 micrograms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heparin",
"       </td>",
"       <td>",
"        1 unit/mL",
"       </td>",
"       <td>",
"        100 units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipid",
"        <sup>",
"         &bull;",
"        </sup>",
"        (by separate infusion)",
"       </td>",
"       <td>",
"        5 mL/kg/day",
"       </td>",
"       <td>",
"        1 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        100 + 5 = 105 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     * This initial TPN solution contains no electrolytes, phosphorus, magnesium, or cysteine. Ongoing monitoring is required for serum glucose (determine whether to increase glucose infusion rate), and electrolytes, phosphorus, magnesium (determine when these are to be added). When phosphorus is added, ensure that cysteine has been added so that solubility of minerals is optimized.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Lipid is administered intravenously through a separate site.",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <ol>",
"      <li>",
"       Nutrition &amp; Gastroenterology Clinical Review Committee. Nutrition support. In: Guidelines for the Acute Care of the Neonate, Adams JM, Garcia-Prats JA, Schanler RJ, et al (Eds), Newborn Section, Department of Pediatrics, Baylor College of Medicine, Houston 2002. p.43.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17116=[""].join("\n");
var outline_f16_45_17116=null;
var title_f16_45_17117="Causes oropharyngeal dysphagia";
var content_f16_45_17117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Representative causes of oropharyngeal dysphagia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Iatrogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Medication side effects (chemotherapy, neuroleptics, etc)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postsurgical muscular or neurogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corrosive (pill injury, intentional)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diptheria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Botulism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mucositis (herpes, cytolomegalovirus, candida, etc)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyloidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cushing's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyrotoxicosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wilson's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Myopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Connective tissue disease (overlap syndrome)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dermatomyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myasthenia gravis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myotonic dystrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oculopharyngeal dystrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polymyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraneoplastic syndromes",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurological",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brainstem tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Head trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stroke",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebral palsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Guillain-Barr&eacute; syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Huntington's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polio",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postpolio syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tardive dyskinesia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metabolic encephalopathies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyotrophic lateral sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Parkinson disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dementia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Structural",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cricopharyngeal bar",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Zenker's diverticulum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cervical webs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oropharyngeal tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteophytes and skeletal abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital (cleft palate, diverticula, pouches, etc)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Cook IJ, Kahrilas PJ. AGA: Technical review: Management of oropharyngeal dysphagia. Gastroenterology 1999; 116:455.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17117=[""].join("\n");
var outline_f16_45_17117=null;
var title_f16_45_17118="Hypoxia in the renal medulla";
var content_f16_45_17118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypoxia in the renal medulla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 176px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Development of medullary hypoxia due to the exchange of oxygen between the descending and ascending limbs of the vasa recta capillaries (straight arrows) and to oxygen consumption by the medullary cells (curved arrows). The net effect is that the PO2 falls to 5 to 10 mmHg in the inner medulla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brezis M, Rosen S, Silva P, Epstein FH, Kidney Int 1984; 26:375. Reprinted by permission from Kidney International.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_45_17118=[""].join("\n");
var outline_f16_45_17118=null;
var title_f16_45_17119="Contents: Hospital hematology";
var content_f16_45_17119=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?2/63/3070\">",
"       Hospital Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital hematology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital hematology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17832\">",
"           Abnormalities of coagulation and platelet function in preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/0/22538\">",
"           Anemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/57/8089\">",
"           Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33348\">",
"           Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/40/33415\">",
"           Anticoagulant and antiplatelet therapy in patients with infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/44/7881\">",
"           Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1258\">",
"           Anticoagulation in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/36/586\">",
"           Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/14/29930\">",
"           Aplastic anemia: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/3/5178\">",
"           Approach to the adult patient with a bleeding diathesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/46/29418\">",
"           Approach to the adult patient with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34346\">",
"           Approach to the adult patient with splenomegaly and other splenic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/19/15674\">",
"           Approach to the adult patient with thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/30/35305\">",
"           Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/3/18489\">",
"           Approach to the diagnosis of hemolytic anemia in the adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/12/3274\">",
"           Approach to the patient with lymphocytosis or lymphocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29511\">",
"           Approach to the patient with neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/6/24681\">",
"           Approach to the patient with thrombocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/22/5482\">",
"           Bone marrow aspiration and biopsy: Indications and technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26234\">",
"           Causes and diagnosis of anemia due to iron deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35705\">",
"           Causes of neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36826\">",
"           Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/6/20586\">",
"           Clinical and laboratory aspects of platelet transfusion therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/20/25929\">",
"           Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8729\">",
"           Clinical features, diagnosis, and treatment of methemoglobinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/13/30938\">",
"           Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/22/25960\">",
"           Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/36/4682\">",
"           Clinical use of coagulation tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9752\">",
"           Clinical use of plasma components",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6646\">",
"           Complications of therapeutic plasma exchange",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/55/31605\">",
"           Controversial areas in preoperative autologous blood donation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/8/30857\">",
"           Correcting excess anticoagulation after warfarin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/27/39353\">",
"           Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14055\">",
"           Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/17/3351\">",
"           Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23017\">",
"           Diagnosis and management of priapism in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/12/33994\">",
"           Diagnosis of suspected deep vein thrombosis of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/1/29721\">",
"           Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24777\">",
"           Diagnostic approach to the patient with polycythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21850\">",
"           Drug-induced neutropenia and agranulocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/40/1673\">",
"           Drug-induced thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/59/19385\">",
"           Evaluation and management of thrombocytopenia by primary care physicians",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39080\">",
"           Evaluation of peripheral lymphadenopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/41/11930\">",
"           Evaluation of the patient with established venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/11/28857\">",
"           General principles in the use of immune globulin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/18/4393\">",
"           Granulocyte transfusions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/54/34664\">",
"           Hematopoietic support after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40890\">",
"           Heparin-induced thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/43/35514\">",
"           Hypercoagulable disorders associated with malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11769\">",
"           Immunologic blood transfusion reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/52/5961\">",
"           Indications for red cell transfusion in the adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12597\">",
"           Indications for therapeutic plasma exchange",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10473\">",
"           Infectious causes of neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/2/24614\">",
"           Laboratory evaluation of neutropenia and neutrophil dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/59/43961\">",
"           Low molecular weight heparin for venous thromboembolic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/3/10298\">",
"           Management of warfarin-associated intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38294\">",
"           Massive blood transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43786\">",
"           Overview of the causes of venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39946\">",
"           Overview of the management of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24073\">",
"           Oxygen carriers as alternatives to red cell transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/56/8073\">",
"           Pathogenesis and etiology of disseminated intravascular coagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/43/32439\">",
"           Preoperative assessment of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/54/12134\">",
"           Preoperative autologous blood donation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/21/36186\">",
"           Prevention of venous thromboembolic disease in medical patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41802\">",
"           Prevention of venous thromboembolic disease in surgical patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27082\">",
"           Pulmonary complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/3/37945\">",
"           Refractoriness to platelet transfusion therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/39/29306\">",
"           Supportive care after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/46/10986\">",
"           The approach to the patient who refuses blood transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/23/44408\">",
"           Therapeutic use of fondaparinux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/8/33930\">",
"           Therapeutic use of heparin and low molecular weight heparin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/17/42266\">",
"           Therapeutic use of warfarin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38442\">",
"           Treatment of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43082\">",
"           Treatment of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/37/21081\">",
"           Use of red blood cells for transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14330\">",
"           Vasoocclusion in sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-3C3DA36DC3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_45_17119=[""].join("\n");
var outline_f16_45_17119=null;
